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ABSTRACT 
David O. Onyango 
BASE EXCISION REPAIR APURINIC/APYRIMIDINIC ENDONUCLEASES IN 
APICOMPLEXAN PARASITE TOXOPLASMA GONDII 
Toxoplasma gondii is an obligate intracellular parasite of the phylum 
Apicomplexa. Toxoplasma infection is a serious threat to immunocompromised 
individuals such as AIDS patients and organ transplant recipients. Side effects 
associated with current drug treatment calls for identification of new drug targets. 
DNA repair is essential for cell viability and proliferation. In addition to reactive 
oxygen species produced as a byproduct of their own metabolism, intracellular 
parasites also have to manage oxidative stress generated as a defense 
mechanism by the host immune response. Most of the oxidative DNA damage is 
repaired through the base excision repair (BER) pathway, of which, the apurinic 
/apyrimidinic (AP) endonucleases are the rate limiting enzymes. Toxoplasma 
possesses two different AP endonucleases. The first, TgAPE, is a magnesium-
dependent homologue of the human APE1 (hAPE1), but considerably divergent 
from hAPE1. The second, TgAPN, is a magnesium-independent homologue of 
yeast (Saccharomyces cerevisiae) APN1 and is not present in mammals. We 
have expressed and purified recombinant versions of TgAPE and TgAPN in E. 
coli and shown AP endonuclease activity. Our data shows that TgAPN is the 
more abundant AP endonuclease and confers protection against a DNA 
damaging agent when over-expressed in Toxoplasma tachyzoites. We also 
generated TgAPN knockdown Toxoplasma tachyzoites to establish that TgAPN is 
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important for parasite protection against DNA damage. We have also identified 
pharmacological inhibitors of TgAPN in a high-throughput screen. The lead 
compound inhibits Toxoplasma replication at concentrations that do not have 
overt toxicity to the host cells. The importance of TgAPN in parasite physiology 
and the fact that humans lack APN1 makes TgAPN a promising candidate for 
drug development to treat toxoplasmosis. 
 
William J Sullivan Jr. Ph.D. - Chairman 
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CHAPTER 1: INTRODUCTION 
1. Toxoplasma overview 
A. Apicomplexan parasites 
Toxoplasma gondii is an obligate intracellular protozoan parasite of the 
phylum Apicomplexa. Phylum Apicomplexa is composed of almost 5,000 
different species of obligate intracellular parasites [1]. The defining characteristic 
of an apicomplexan parasite is the collection of specialized organelles 
(micronemes, rhoptries and polar rings) at the apical end that help the parasites 
invade the host cell. Apicomplexa infect a wide range of cells from warm blooded 
animals ranging from birds to mammals [1].  
The complex life cycle of apicomplexan parasites can be divided into three 
general stages: sporogony, merogony and gametogony, which can slightly differ 
among the species. The life cycle stages can also be distinguished between the 
sexual and asexual stages. In monoxenous species all stages occur in the same 
host animal, while in heteroxenous species they occur in different hosts animals 
[1]. 
Apicomplexa are important human and livestock pathogens that lead to 
serious economic burden in agriculture and the healthcare system [2]. The three 
most important pathogenistic apicomplexans to humans are: Plasmodium, 
Toxoplasma and Cryptosporidium. While Plasmodium accounts for the highest 
mortality rates for any apicomplexan parasite in humans, Toxoplasma emerged 
as a serious opportunistic pathogen during the AIDS epidemic [3]. 
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B. Toxoplasma as a model apicomplexan 
Other than being an important pathogen, Toxoplasma gondii is considered 
a model organism for the study of apicomplexan parasite biology. Unlike other 
members of the phylum Apicomplexa, such as Plasmodium and 
Cryptosporidium, Toxoplasma is more amenable to genetic manipulation in the 
laboratory. Cell biology studies are easily performed in Toxoplasma through 
transient and stable transfection. Toxoplasma can infect a wide variety of host 
cells and is comparatively easy to culture in vitro [4]. The Toxoplasma genome 
has been sequenced to >12X coverage and is an invaluable resource for the 
study of the parasite. The genomic information is made available at 
http://www.toxoDB.org. Therapeutic agents used against Toxoplasma are in 
some cases successful against Plasmodium [5]. Therefore, identifying new drug 
targets and therapeutic agents against Toxoplasma may be useful against other 
apicomplexan parasites. 
C. Life cycle 
Toxoplasma has a complex life cycle that involves multiple hosts 
throughout its different stages of development. Toxoplasma is a heteroxenous 
apicomplexan. The life cycle consists of a sexual phase that only occurs in the 
cat intestine, which is the definitive host. Toxoplasma must infect a cat to 
undergo a complete life cycle. The cats become infected with the parasite by 
eating prey that has cysts in its tissue. In the cat intestine, the parasite 
reproduces sexually culminating in the production of oocysts that are shed with 
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the cat feces. The oocysts are very hardy and can survive for several months, 
remaining capable of infecting a new host when ingested or inhaled [6]. 
Intermediate hosts such as humans and livestock become infected when 
the oocysts or bradyzoites are ingested. Once ingested, the bradyzoites inside 
the tissue cyst or the sporozoites inside the oocyst penetrate the epithelial cells 
of the intestines and infect different cells and tissues. The parasite has a 
predilection for heart, muscle and brain tissue, where it causes tissue damage 
and form cysts. The tissue cysts can survive in the host tissue indefinitely and 
sometimes for the duration of the host’s life [6]. 
There are three stages of Toxoplasma: the tachyzoites (rapidly growing 
stage), the bradyzoites (slow growing stage in tissue cysts), and the sporozoites 
(in oocysts). These stages are linked in a complex life cycle: 
Tachyzoites. The tachyzoite is crescent shaped and is the stage that was 
first identified in the North African rodent gundi [6]. This stage has also been 
called a trophozoite, the proliferative form, the feeding form, and the endozoite. It 
divides into two by a specialized process called endodyogeny, which is similar to 
binary fission. The tachyzoites are responsible for the acute phase of 
Toxoplasma infection. 
Bradyzoite and tissue cysts. The bradyzoite is the encysted form of the 
parasite in the host tissues. Bradyzoites are also called cystozoites. The cyst wall 
is destroyed by pepsin or trypsin, but the cystic organisms are resistant to 
digestion by gastric juices (pepsin and HCl). In contrast, tachyzoites are not 
resistant to digestive enzymes. Bradyzoites invade the host intestinal cells, 
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converting into tachyzoites, and ultimately infecting other tissues in the host’s 
body. Tissue cysts are important in the life cycle of Toxoplasma because 
carnivorous hosts can become infected by ingesting infected meat [7]. The 
bradyzoites are slow growing and are responsible for chronic/latent 
toxoplasmosis. 
Enteroepithelial, asexual and sexual stages. The cat intestine is the only 
environment that Toxoplasma sexual reproduction takes place. Also 
differentiation into micro and macrogametes, fertilization, up to formation of 
oocysts occurs. Asexual development of Toxoplasma can also occur in the 
enterocytes of the cat and are designated as the asexual enteroepithelial stages. 
The enteroepithelial stages are distinguished morphologically from tachyzoites 
and bradyzoites, which also occur in cat intestine. Fewer than 30% of cats shed 
oocysts after ingesting Toxoplasma cysts in prey tissue [7].  
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Figure 1: Life cycle and transmission of Toxoplasma. There are three stages: 
tachyzoites (rapidly replicating form), bradyzoites (slow replicating form in tissue 
cysts) and sporozoites in oocysts shed by the cat. The definitive host of 
Toxoplasma is the cat (or other felids), and it is within the cat’s gut that the 
sexual cycle of the parasites takes place, resulting in the formation of oocysts. An 
infected cat will shed highly infectious oocysts into the environment. Livestock 
consume the oocysts that become tachyzoites and ultimately bradyzoites in 
animal tissue. If humans consume oocysts from the environment or tissue cysts 
from undercooked meat, they become infected. Tachyzoites are the active form 
of the parasite responsible for tissue destruction and disease symptoms. 
Tachyzoites can cross the placenta and cause congenital infection of the fetus if 
a woman becomes infected for the first time during pregnancy.  
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D. Transmission 
Vertical transmission 
  Congenital. Congenital Toxoplasma infection in a human child was initially 
described by Wolf, Cowen, and Page (1939) and later found to occur in many 
species of animals, particularly sheep, goats, and rodents [86]. Congenital 
toxoplasmosis occurs when the mother becomes infected with Toxoplasma for 
the first time during pregnancy and the tachyzoites cross the placental barrier. 
Congenital infections can be repeated in some strains of mice with infected mice 
producing congenitally infected offspring for several generations [8].  
Carnivorism. Congenital transmission occurs too rarely to explain 
widespread infection in man and animals worldwide. It has been suggested that 
most transmissions might occur through the ingestion of undercooked meat [9]. 
Evidence to support this idea was obtained by demonstrating that Toxoplasma 
bradyzoites are resistant to proteolytic enzymes. The tissue cyst wall is 
immediately dissolved by such enzymes, but the released bradyzoites survive to 
penetrate the intestinal epithelial cells of the host. Epidemiological evidence 
indicates toxoplasmosis is common in humans in some localities where raw meat 
is routinely eaten [9]. Populations that eat undercooked meat are also at risk of 
infection. 
Fecal-oral transmission. Toxoplasma oocysts shed by felids can also 
cause Toxoplasma infection if ingested or inhaled. In approximately 3 days from 
being passed in the stool, the oocysts mature and become infective to other 
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animals [10]. A risk factor for toxoplasmosis is contact with oocysts from cat 
feces contaminating water, soil and the food supply. 
Regular contact with cat feces such as in cat litter is a predisposing factor 
for infection to humans in their living environment [10]. 
E. Epidemiology 
Toxoplasma is a parasite with a broad spectrum of hosts ranging from 
birds to mammals. The definitive host of the parasite is the cat, which sheds 
oocysts that infect other animals including humans. The estimated worldwide 
seroprevalance for Toxoplasma in domestic cats is 30–40% [11]. Numerous farm 
animals are also afflicted with toxoplasmosis. Perhaps the most striking example 
is that of sheep farming, where economic losses from sheep abortions due to 
congenital toxoplasmosis are significant [12]. Since sheep are not carnivorous, 
they most likely acquire the infection through oocysts in their feed [86]. The 
marine environment has generally been considered too harsh for the survival of 
Toxoplasma, but marine mammals are unexpectedly susceptible to infection [13]. 
Among the affected marine mammals are seals, sea lions, and dolphins. The 
spread of toxoplasmosis into the marine population is alarming as it threatens 
animals that are already endangered and at risk of extinction [14]. 
Toxoplasma is found in humans, worldwide, under a variety of climates 
and socio-economic circumstances. The seroprevalence of Toxoplasma in the 
United States is as high as 40% [9]. The emergence of the AIDS epidemic has 
made Toxoplasma infection a more serious threat to global health. Death as a 
result of toxoplasmosis in AIDS patients ranges from 10% in the United States 
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and 30% in Europe [15]. Toxoplasma can also cross the placental barrier and 
cause congenital toxoplasmosis, which might lead to blindness, hydrocephalus, 
and mental retardation. The Toxoplasma infection can also cause spontaneous 
abortion. Four hundred to four thousand infants are affected by congenital 
toxoplasmosis in the United States each year at a cost of $7.7 billion [16]. 
F. Toxoplasma as an opportunistic pathogen 
Toxoplasma has emerged as a serious threat in immunocompromised 
individuals such as AIDS patients, cancer chemotherapy recipients, and organ 
transplant recipients. The reactivation of a previously acquired and chronic 
infection is the main cause of toxoplasmic encephalitis in AIDS patients, and it 
has been closely related to the severity and progression of immunosuppression. 
Immunocompetent persons with a primary infection are usually asymptomatic, 
but latent infection can persist for life [17]. In immunosuppressed patients, such 
as patients with AIDS, the parasite can reactivate and cause disease when the 
CD4 lymphocyte count drops below 100 cells/μL. Patients with AIDS and CD4 
counts <100 cells/μL who are seropositive for Toxoplasma have a 30% 
probability of developing reactivated toxoplasmosis if they are not receiving 
effective prophylactic treatment; the most common site of reactivation is the 
central nervous system [18]. 
In transplant recipients, this risk of reactivation also exists for those who 
are seropositive for Toxoplasma. The infection is closely related to the degree 
and duration of immunodeficiency and, therefore, markedly differs according to 
the type of transplantation. At the chronic stage of toxoplasmosis, tissue cysts 
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are formed in the neural and muscular tissues, including the brain, eyes, skeletal 
muscles and cardiac muscles, but may also develop in visceral organs, including 
the lungs, liver and kidneys which can be transplanted [19]. Most cases of 
toxoplasmosis in heart and heart–lung transplantation have been reported in 
seronegative recipients receiving a heart transplant from a seropositive donor. 
Clinical symptoms usually occur in the first 3 months after transplantation and 
consist of febrile myocarditis, encephalitis or pneumonitis [20]. Thus, 
toxoplasmosis represents a major infectious complication in transplant recipients 
that can be prevented. This can be achieved by serological screening of the 
organ donor and recipient, screening for toxoplasmosis after the transplant, and 
treatment with sulfadiazine and pyrimethamine of the organ recipient [21]. 
G. Types of Toxoplasma infection 
Congenital Toxoplasmosis 
Toxoplasma can cross the placental barrier of an infected pregnant 
mother and infect the fetus, resulting congenital toxoplasmosis. Congenital 
toxoplasmosis can lead to encephalitis, hydrocephalus with intracranial 
calcification, chorioretinitis with scarring and loss of vision, hepatitis, and 
lymphadenopathy [22]. Children who survive to birth may subsequently develop 
toxoplasmosis-associated injuries, including deafness, microcephaly, and mental 
deficiencies [23]. 
Early treatment may prevent the further progress of the infectious process 
and the development of disabilities in children [24]. If Toxoplasma is detected in 
the amniotic fluid and if ultrasound examination is normal, a prescription of 
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pyrimethamine and sulfonamides, together with folic acid, can be administered 
[25]. In the case of cerebral microcalcifications or hydrocephaly diagnosed by 
ultrasound, a termination of pregnancy may be proposed to the parents. After 
birth, the infected child is treated with pyrimethamine and sulfonamides for 12 
months. Spiramycin, which does not cross the placental barrier, is used in 
attempt to minimize transmission to the fetus during pregnancy. Pyrimethamine, 
spiramycin and sulfonamides are well tolerated in neonates and they are non-
teratogenic, although sulfonamides might result in kernicterus (bilirubin cerebral 
toxicity) in the neonates [26]. 
Cerebral toxoplasmosis  
Cerebral toxoplasmosis is one of the most common opportunistic 
neurological infections in AIDS patients, and it is typically observed in the later 
stages of human immunodeficiency virus (HIV) infection. The infection may 
involve the brain diffusely or form discrete abscesses. Clinical manifestations 
include seizures, headache, focal neurologic deficits, and intercranial 
hypertension [27]. Highly active antiretroviral therapy (HAART) has decreased 
the incidence of cerebral toxoplasmosis by boosting the host’s immunity. 
Currently, the prevalence of Toxoplasma induced focal brain disorders still 
accounts for a considerable proportion of mortality and morbidity in AIDS 
patients, especially in developing countries [28]. Cerebral toxoplasmosis requires 
long-term treatment with pyrimethamine-sulfadiazine or a pyrimethamine-
clindamycin regime. 
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Ocular Toxoplasmosis 
Ocular toxoplasmosis is one of the most frequent causes of posterior 
uveitis. An ocular reactivation of the disease can occur when the cysts are 
present within the retina and the patient becomes immunocompromised. 
Epidemiological data suggests that most cases of ocular toxoplasmosis result 
from reactivation of ocular toxoplasmosis rather than a new infection. Symptoms 
vary, but generally consist of unilateral floaters or blurred vision when the 
disease becomes active. Inactive disease rarely causes visual symptoms unless 
scarring is near the central retina or macula. The slit-lamp examination reveals 
the presence of a granulomatous inflammation, a mild to moderate anterior 
chamber inflammation [30]. Fundoscopy reveals the presence of a yellow focus 
of retinochoroiditis [29]. Severe cases of ocular toxoplasmosis might result in 
visual impairment and blindness. Pyrimethamine-sulfadiazine regime as well as 
trimethoprim-sulfamethoxazole regime is used for the treatment of ocular 
toxoplasmosis. 
Cutaneous Toxoplasmosis 
A less common manifestation of Toxoplasma infection is the cutaneous 
form that shows up as lesions on the patient’s skin. Skin involvement in 
toxoplasmosis is rare even in severely immunosuppressed individuals. 
Cutaneous toxoplasmosis is diagnosed by a biopsy of the skin lesion to reveal 
tachyzoites [31].  
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H. Diagnosis 
Diagnosis of Toxoplasma infection occurs mainly through serological 
testing, which is also important in determining the prevalence of the infection in a 
population. The Sabin–Feldman test, which is among the most widely used, 
makes use of Toxoplasma tachyzoites derived from live culture, which are 
incubated with test serum and complement, followed by addition of a Sabin–
Feldman dye. If the test serum comes from an individual infected with 
Toxoplasma, then the specific antibodies in the serum will recognize and bind to 
the parasite and fix the complement, resulting in lysis of the tachyzoites, which 
will appear as unstained when examined under a microscope [32]. Enzyme 
linked immunosorbent assay (ELISA) tests are also a reliable method to detect 
Toxoplasma-specific antibodies in humans. Another less commonly used method 
is the use of polymerase chain reaction (PCR), which detects Toxoplasma-
specific DNA sequences [33]. 
I. Treatment and prevention 
There are a variety of steps that can be taken to avoid becoming infected 
with Toxoplasma. Animal vaccines have successfully been used in the sheep 
industry to reduce Toxoplasma-induced abortion. 
 In humans, limiting contact with infective bradyzoites and oocysts is the 
most effective way to prevent infection. Good hygiene e.g. hand washing after 
soil contact, washing fruits and vegetables that are eaten raw, freezing meat at -
12°C for 24 hours and/or cooking meat until an internal temperature of 66°C is 
reached, and not drinking untreated water, help prevent infection. Serological 
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screening during pregnancies and organ transplants can be administered to 
prevent spread of the parasites. 
The current drug treatment of pyrimethamine and sulfadiazine has been in 
use since the 1950s. These two drugs target the folic acid synthesis pathway by 
inhibiting dihydrofolic acid reductase (DHFR) and dihydropteroate synthase 
(DHPS), respectively [34]. Spiramycin is used almost exclusively for cases of 
toxoplasmosis during pregnancy as it does not cross the placental barrier. 
Clindamycin or atovaquone are used in patients with sulfonamide allergies. The 
current drugs available for treatment of toxoplasmosis are limited as they cause 
severe side effects, such as skin rash and epidermal necrosis from sulfonamide 
toxicity. Pyrimethamine causes bone marrow suppression and megaloblastic 
anemia, which can be life-threatening [35]. The existing drug treatments are also 
limited to targeting the tachyzoite stage, as they do not kill bradyzoites protected 
by the cyst wall.  
J. Immune response 
In immunocompetent people, infection with Toxoplasma results in the 
development of protective immune response against the disease. As a result of 
the robust immune response, there have been several attempts to develop 
effective vaccines to combat the disease [36]. The importance of the immune 
system in protecting the host against Toxoplasma infection was dramatically 
emphasized with the emergence of AIDS in the 1980s. During the earliest stages 
of infection, Toxoplasma is able to induce the nonspecific activation of 
macrophages, NK cells, and other cells such as fibroblasts, epithelial, or 
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endothelial cells. This initial response peaks at the end of the first week and then 
slowly reduces until absent by the end of the second week. The activation of 
macrophages by the cytokine interferon gamma (IFN-γ) in the presence of co-
signals, such as tumor necrosis factor-α (TNF-α), is necessary to induce the 
cytotoxic activity of the macrophages against Toxoplasma. IFN-γ activates the 
macrophages by increasing oxidative metabolism, releasing hydrogen peroxide, 
which damages DNA, lipids and proteins in cells [38]. Nitric oxide (NO) produced 
by macrophages activated by IFN-γ also restricts parasite growth during the 
chronic phase. IFN-γ also increases the activity of indoleamine 2, 3-dioxygenase, 
resulting in the breakdown of tryptophan, an amino acid required for growth of 
the parasite [37]. Toxoplasma cysts are protected from the immune system and 
can remain in host tissue for life. The antibodies in the humoral immune 
response and the complement system play a minor but important role in limiting 
the acute infection [39]. Toxoplasma has evolved the ability to prevent the 
translocation of STAT1 and NF- β to the nucleus, which prevents macrophages 
from producing IL12 and TNF-α, thereby enabling the parasite to subvert the host 
immune system [40]. 
K. Toxoplasma adaptations to the host cell environment 
Toxoplasma is well adapted to invade and survive in the host cell. Like 
other apicomplexan parasites, Toxoplasma has a highly specialized protein 
secretion mechanism at its apical end that facilitates host cell invasion. During 
invasion, the contents of three separate secretory systems are discharged 
sequentially to allow adherence and consequently invasion of the cell. The 
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parasite secretes microneme and rhoptry proteins to form a parasitophorous 
vacuole membrane (PVM). The parasitophorous vacuole (PV) acts as a 
protective environment for the parasites in the host cell by avoiding endosome 
fusion [41]. The PVM also enables the parasites to obtain nutrients and other 
requirements such as amino acids and nucleotides from the host cell [42]. The 
PVM occupies the perinuclear region of the host cell, recruits host mitochondria 
and traffics along the host cell microtubules. Simple sugars, amino acids, 
nucleobases and cofactors are able to go through the PVM pores for use by the 
parasites [42]. Metabolites from the parasite can also pass through the PVM into 
the host cell cytoplasm. Toxoplasma is also able to take up lipids such as 
cholesterol through an intricate salvage pathway [43]. 
Toxoplasma also prevents apoptosis of the host cell. Apoptosis is a 
common strategy that cells infected with viruses and bacteria employ to minimize 
the spread of the infection. Toxoplasma has developed the ability to inhibit 
apoptosis of the host cell [44]. Live Toxoplasma can prevent apoptosis in 
cultured cells exposed to apoptotic inducers including ultraviolet rays and 
irradiation [45].  
Reactive oxygen species (ROS) are a constant stress for parasites in the 
intracellular environment, especially in immune effector cells such as 
macrophages and neutrophils during the oxidative burst [47]. Toxoplasma has an 
advanced antioxidant system made up of superoxide dismutase, catalase, 
glutathione peroxidase and peroxiredoxins, which serve to protect the parasite 
against reactive oxygen species [46].  
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2. DNA damage and repair 
A. Importance of DNA integrity and health implications 
Maintenance of DNA integrity is essential for all cells and life forms. It is 
the prime objective of all organisms to pass their genetic material intact and 
unmutated to ensure survival and continuity of the species. However, DNA is 
constantly exposed to numerous endogenous and exogenous insults that cause 
damage to its stability as well as integrity. To counter this threat, cells have 
evolved intricate defense mechanisms that protect the DNA from damage and 
also repair any damage that occurs. Failure to protect and repair damaged DNA 
may result in deleterious mutations, disease, and cell death. The human genome 
experiences tens of thousands of DNA lesions each day [47]. These lesions are 
a serious threat to the normal function of each cell by causing problems in 
replication and transcription. If the DNA lesion is not properly repaired, mutations 
may result, compromising genomic stability and threatening cell viability. 
Improved understanding of DNA repair mechanisms is an important element in 
understanding the nature of many diseases, including cancer. 
Paradoxically, DNA damage and mutations can actually be beneficial in 
cells and therapeutics. DNA damage can be used in the treatment of cancer by 
using DNA damaging drugs and radiation to target the cancer cells. The 
production of diverse antibodies and antibody classes are dependent on 
mutations resulting from reduced polymerase fidelity and weaker DNA damage 
response. Impaired DNA damage response will result in an impaired immune 
system by limiting antibody diversity [48]. 
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DNA damage plays an important role in the life cycle of parasites and the 
progression of infectious disease. Mutations in a pathogen’s genome facilitate 
the acquisition of traits that may limit the effectiveness of the host immune 
system and drug therapies. The integration of viral DNA into the host genome 
ensures its continued presence in the life of the host and, in some cases, even in 
host progeny. In addition, certain pathogens use DNA damage response 
mechanisms to promote virulence. For example, African trypanosomes evade 
host immune surveillance by using homologous recombination and mutations to 
periodically alter their protective variant-surface-glycoprotein coat [49]. DNA 
damage and repair has thus been proposed to be an attractive target in the 
treatment of infectious disease. 
B. Sources of DNA damage 
The sources of DNA damage can generally be divided into exogenous and 
endogenous causes. Exogenous causes include a wide range of insults such as 
mutagenic chemicals in the environment as well as physical damage from 
ionizing radiation. Exogenous damage was once thought to be responsible for 
the majority of DNA damage in cells, but recent studies have shown that most 
DNA damage actually occurs endogenously, as a result of normal cellular 
metabolic activity [50].  
Abasic or apurinic/apyrimidinic (AP) sites are common DNA lesions that 
can be caused by both exogenous and endogenous insults. AP sites can be 
produced by spontaneous hydrolysis, alkylation-induced hydrolysis, or 
glycosylase-catalyzed base-excision repair. DNA bases are susceptible to 
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spontaneous hydrolytic deamination. 100 to 500 cytosines are spontaneously 
deaminated to uracil every day in human cells. If not immediately corrected, such 
changes can lead to transition mutations. Uracil glycosylases rapidly remove 
uracil from DNA, leaving an abasic site. The glycosidic bond between bases and 
deoxyribose in DNA is labile under certain conditions, such as heating, alkylation 
of bases, or the action of N-glycosylases. Cleavage of the glycosidic bond in 
DNA also leads to an abasic site [51]. 
Produced as a result of cellular metabolism as well as other biochemical 
reactions and external factors, reactive oxygen species (ROS) are perhaps the 
most abundant genotoxic element in the cell. ROS include superoxide, hydrogen 
peroxide, hydroxyl radicals, and singlet oxygen. ROS cause damage by oxidizing 
DNA bases and sugars, which might lead to strand breakage. The damaged 
bases are removed by specific glycosylases such as Ogg1, leaving an abasic 
site [51]. 
DNA damage can also occur as a result of alkylation of the bases. The 
most common DNA alkylation agent is S-adenosylmethionine (SAM) [52]. It is a 
reactive methyl group donor contributing to physiological enzymatic DNA 
methylation, which plays a role in regulation of gene expression. Aberrant 
methylation by SAM can result in alkyl damage in bases. Some alkylation 
damage to bases, such as guanine methylation, is highly mutagenic. In most 
cases, the damaged base is recognized and removed by a specific glycosylase 
leaving an abasic site [51]. 
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There are less characterized sources of DNA damage that still play an 
important role in the stability of the genome. Such damage includes the products 
of lipid peroxidation, which are highly reactive and cause DNA lesions [88]. 
Several oestrogen metabolites can cause DNA damage directly or indirectly 
through redox cycling processes that generate reactive radical species [87]. 
Spontaneous DNA strand breakage is also a source of DNA damage that is 
ultimately cytotoxic if not repaired [51]. 
C. Cell response to DNA damage 
In the event of DNA damage, a cell has a wide range of responses 
depending on the type and extent of damage. These DNA damage response 
reactions include: (i) removal of DNA damage and repair of the DNA, (ii) 
activation of a DNA damage checkpoint, which arrests cell cycle progression so 
as to allow for repair and prevent the transmission of damaged or incompletely 
replicated chromosomes, (iii) a transcriptional response, which causes changes 
in gene expression that may be beneficial to the cell, (iv) DNA damage bypass 
polymerases, and (v) apoptosis, which eliminates heavily damaged or seriously 
deregulated cells [53]. 
Severely damaged DNA that cannot be repaired usually triggers an 
apoptotic response. Apoptosis induced by DNA damage is indistinguishable from 
genetically programmed cell death that occurs during development of a variety of 
tissues. The severe damage induces the activation of caspases to initiate 
apoptosis. However, in extreme cases of DNA damage, cells may undergo a 
necrotic death [53]. 
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The detection and subsequent removal of DNA damage is not completely 
efficient. Some DNA lesions are persistent and may not be adequately repaired. 
DNA replication, transcription or recombination machineries may encounter sites 
of DNA damage before they are repaired. DNA damage tolerance allows cells to 
overcome the potentially lethal effects of blocked replication and transcription 
until a time when the damage can be removed. Higher eukaryotes have multiple 
specialized polymerases that have low fidelity and can bypass damage sites on 
DNA. These low fidelity polymerases are utilized in the diversification of 
antibodies in the immune system [54].  
DNA damage activates cell cycle checkpoints to prevent progression of 
the damage and minimize mutations. DNA damage checkpoints are biochemical 
pathways that delay or arrest cell cycle progression in response to DNA damage. 
The DNA damage checkpoints employ damage sensor proteins, such as ATM 
(Ataxia telangiectasia mutated), ATR (Ataxia telangiectasia related), the Rad17-
RFC complex, and the 9-1-1 complex, to detect DNA damage and initiate signal 
transduction cascades to repair it [55]. DNA damage checkpoints also facilitate 
the transcription of genes that help remedy the damage [55]. 
Cells respond to DNA insults by trying to repair the damage and maintain 
the integrity of the genome. There are numerous DNA repair pathways that work 
independently as well as in concert to maintain DNA integrity. The pathway to 
repair DNA is mainly dictated by the type of damage incurred. The most common 
DNA repair pathways include nucleotide excision repair (NER), homologous 
recombination (HR), non-homologous end joining repair (NHEJ), mismatch 
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repair, and base excision repair (BER). As it is central to my thesis, BER will be 
described in detail. 
D. Base excision repair  
Base excision repair (BER) is the primary DNA repair pathway that 
corrects base lesions that arise due to oxidative, alkylation, deamination, and 
depurinatiation/depyrimidination damage. The first step in BER is the recognition 
of a damaged base by a DNA glycosylase (Figure 2). After recognition of the 
damaged base by the appropriate DNA glycosylase, this glycosylase catalyzes 
the cleavage of an N-glycosidic bond, effectively removing the damaged base 
and creating an apurinic /apyrimidinic site (AP site). Following the removal of the 
damaged base, AP endonucleases cleave the phosphate backbone 5’ of the 
abasic site. DNA lyase activity (present in some glycosylases) can also cleave 
the phosphate backbone 3’ to the abasic site. The newly created nick is 
processed by the AP endonuclease, creating a single nucleotide gap in the DNA. 
Importantly, the gap contains a 3’-hydroxyl and a 5’-phosphate, substrates 
compatible with the downstream enzymatic reactions in BER. A DNA polymerase 
fills in the gap with the correct nucleotide. Finally, a DNA ligase completes the 
repair process and restores the integrity of the helix by sealing the nick (Figure 
2). 
Glycosylases recognize specific damaged bases and excise them from 
the genome, effectively initiating BER. There are numerous DNA glycosylases 
that are specific for different types of base damage; to date, there are 11 
characterized mammalian glycosylases. DNA glycosylases fall into two major 
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classes that differ with respect to catalytic mechanism. Monofunctional 
glycosylases catalyze the single-step displacement of the damaged base. 
Bifunctional DNA glycosylases also excise the lesion base as well as the DNA 
backbone on the 3′ side of the AP site followed in some cases by backbone 
severance on the 5′ side as well [56].  
BER remedies DNA damage through two general pathways: short-patch 
and long-patch. The short-patch BER pathway leads to repair of a single 
nucleotide while the long-patch BER pathway produces a repair tract of at least 
two nucleotides. How the cell decides to repair damage through short-patch or 
long-patch BER is poorly understood. One hypothesis suggests that the switch 
from short-patch to long-patch BER depends on the relative ATP concentration 
near the AP site [57]. It has been shown that long-patch BER occurs more 
frequently at low ATP concentrations, whereas short-patch BER appears to be 
the preferred mechanism with elevated concentrations of ATP. Another 
hypothesis is that BER proceeds through the short-patch pathway if the 
deoxyribophosphate (dRP) can be efficiently removed by 
deoxyribophosphodiesterase (dRP) lyase activity of POLβ. However, if the dRP 
cannot be effectively removed, the BER pathway proceeds by the long-patch 
mechanism, apparently to avoid generating a nick that is refractory to the action 
of a DNA ligase [58]. 
XRCC1 is one of the first proteins recruited to the nick generated by the 
action of a glycosylase and/or AP endonuclease in short-patch BER. XRCC1 has 
no enzymatic activity but is considered an important scaffolding protein in BER. 
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Long-patch BER requires proliferating cell nuclear antigen (PCNA). Polymerase 
delta and polymerase epsilon are required for long-patch BER in a PCNA-
dependent manner, displacing more than one base. The strand displacement 
activity of polymerase delta and epsilon produces a flapped substrate that is 
refractory to ligation. Flap endonuclease 1(FEN1) resolves the problem of an 
unligatable DNA junction by catalyzing the removal of the flap generated by 
polymerase activity [55]. 
The one-nucleotide short-patch BER pathway is completed by the action 
of DNA ligase III. Alternatively, DNA ligase I completes the ligation of the nick in 
long-patch BER. 
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Figure 2: Representation of the base excision repair pathway. This figure shows 
the proteins and DNA interactions in both the short-patch (left branch) and long-
patch (right branch) mammalian BER pathways. Damaged base (represented by 
X) is recognized and excised by a specific DNA glycosylase, generating an AP 
site. AP endonuclease, the rate limiting enzyme, then hydrolyzes the 
phosphodiester bond 5’ to the AP site. The repair can at this point follow either 
short-patch or long-patch pathways. Finally, the resulting nucleotide gap is filled 
through the action of DNA polymerase and a ligase seals the repaired strand.  
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E. AP endonucleases 
AP endonucleases are the rate limiting enzymes of the BER pathway. 
There are two main families of AP endonucleases based on their homology to E. 
coli endonucleases: exonuclease III (Exo III) and endonuclease IV (Endo IV) [59]. 
Structural studies of representative enzymes of the two families reveal similarities 
as well as differences in the mode of action on AP sites. The fact that these two 
decidedly different enzymes have evolved independently to process AP sites 
highlights the biological need for DNA repair. 
Analysis of both the cleaved and uncleaved AP–DNA complexes of both 
Exo III and Endo IV reveals that they employ similar strategies to cleave the 
target phosphate bond. Despite different structural chemistries at their active 
sites, the proposed reaction mechanisms both involve enzyme-activated hydroxyl 
nucleophile attack on the target phosphorus atom [60]. 
Exonuclease III family 
The Endonuclease III family consists of AP endonucleases that are small 
(30,000 to 40,000 Da) monomeric divalent-metal ion dependent enzymes. APE1 
enzymes can be inactivated by metal-chelating agents such as 
ethylenediaminetetraacetic acid (EDTA). The structure of Exo III (E. Coli 
homologue) revealed the characteristic four-layered α,β-sandwich fold, which is 
conserved in the human homologue APE1. Conserved amino acids essential for 
nucleolytic activity are concentrated around the active site and divalent metal-ion 
(Mg2+) binding site [60]. 
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Crystal structures of human APE1 bound to synthetic abasic site-
containing DNA, both with and without the divalent metal ion, show how APE1 
recognizes abasic sites and cleaves the target bond. APE1 binds a flipped-out 
abasic nucleotide with residues penetrating both the DNA minor and major 
grooves. The enzyme-bound AP–DNA is bent at 35° and there is a large 
displacement, or kinking, of the DNA helical axis [60]. 
Endonuclease IV family 
Endo IV family members are small (30,000 Da) Zn2+-dependent 
endonucleases that, unlike the Mg2+-dependent Exo III family of AP 
endonucleases, resist inactivation by EDTA. The structure reveal that Endo IV is 
a single domain αβ protein with secondary structure elements arranged as a β-
barrel having eight parallel β-strands surrounded by eight peripheral α-helices. 
The structure is conserved in the Saccharomyces cerevisiae homologue, APN1. 
Endo IV enzymes have a trinuclear zinc cluster in their active sites. Two of the Zn 
atoms are bridged by a tightly bound water molecule, which is likely deprotonated 
in the enzyme active site, and acts as the nucleophile in the hydrolysis reaction. 
The third zinc atom plays a role in stabilizing the 3′ hydroxyl group produced in 
the reaction. 
Crystal structure studies of Endo IV bound to a synthetic abasic site-
containing DNA revealed the structural features that underlie AP site recognition 
and cleavage. In the Endo IV:DNA complex structure, the AP–DNA is not kinked 
but instead is bent by 90° with both the abasic site and its partner nucleotide 
flipped out of the DNA helix for cleavage [60]. 
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F. DNA repair in parasites and Toxoplasma 
In general, protozoan parasites are highly sensitive to hydrogen peroxide 
and other organic peroxides as well as drug-generated and phagocyte induced 
ROS [61]. Likewise, resistance to ROS has been linked to virulence of some 
species of parasites. Despite the effectiveness of ROS in killing protozoan 
parasites, little is known about the DNA repair and antioxidant mechanisms of 
parasites. 
Parasites are especially vulnerable to DNA damage by the ROS from 
immune effector cells. Not only do parasites have to ensure the integrity of 
nuclear and mitochondrial DNA in a manner analogous to other eukaryotes, 
many parasites possess other extra-nuclear DNA, including extra-chromosomal 
DNA elements in the apicoplast of apicomplexans and the kinetoplast of 
kinetoplastids [62]. Thus, parasites would be more dependent on accurate DNA 
repair. 
The first line of defense the parasites utilize to protect their DNA is to 
neutralize the genotoxic elements before they damage the DNA. Parasites have 
evolved a complex network of antioxidants consisting of enzymatic and non-
enzymatic components. Key among antioxidant enzymes are superoxide 
dismutases (SODs), catalases and peroxidases. One of the most ubiquitous non-
enzyme antioxidants is the tripeptide glutathione (GSH). Toxoplasma also 
possesses effective antioxidant defenses, particularly to contend with ROS 
produced by macrophages and neutrophils. Toxoplasma antioxidants include 
three SODs and glutathione as well as thioredoxin-dependent peroxidases of the 
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peroxiredoxin family. Toxoplasma also possesses a cytoplasmic catalase that 
protects the parasite from hydrogen peroxide [63]. 
DNA repair mechanisms have been studied in kinetoplastids Leishmania 
major and Trypanosoma cruzi [71]. Over-expression of AP endonucleases (ExoIII 
homologue) in these parasites protects them from alkylating and oxidizing DNA 
damaging agents. AP endonucleases from Leishmania and Trypanosoma can 
complement exonuclease III deficiency in E. coli. 
Among Apicomplexa, DNA repair has been studied in Plasmodium 
falciparum. In vitro experiments have shown that the malaria parasite is capable 
of repairing damaged bases through the base excision pathway. The 
experiments showed that malaria parasites contain glycosylase as well as AP 
endonuclease activities [65]. This data indicate that the BER pathway may be 
conserved in Apicomplexa. Further evidence of the BER pathway in Apicomplexa 
comes from the discovery of a FEN-1 homologue, PfFEN-1 in P. falciparum. 
FEN-1 is a key enzyme in long-patch BER in other eukaryotic cells [64]. 
There is virtually no characterization of DNA repair pathways in 
Toxoplasma. Reports are limited to the identification of DNA repair enzymes in 
Toxoplasma. TgDRE (Tg DNA repair enzyme), a homologue of DRT111 of 
Arabidopsis thaliana, and TgPREX (Plastid replication and Repair Enzyme 
Complex) are among the few identified [66]. TgDRE is capable of complementing 
an Escherichia coli mutant lacking ruvC endonuclease and recG helicase. 
TgPREX has been identified as a possible apicoplast DNA repair enzyme. No 
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enzymes of the BER pathway have been previously characterized in 
Toxoplasma. 
Damaged bases in Toxoplasma are likely to be repaired through BER as 
suggested by studies of Plasmodium. Comparative genomics studies performed 
in our laboratory have revealed that apicomplexan parasites possess both 
exonuclease III and endonuclease IV homologues. Toxoplasma, for example, 
has homologues to exonuclease III (TgAPE) and endonuclease IV (TgAPN). 
TgAPE is a homologue of human APE1, but is considerably divergent. TgAPN is 
a homologue of yeast (S. cerevisiae) APN1 and is not present in mammals.  
3. Pharmacological inhibition of DNA repair enzymes 
Inhibition of the DNA repair process as a therapeutic approach has been 
explored in the treatment of cancer. Scientists have previously focused on 
preventing cancer cells from repairing the damage to their DNA by 
chemotherapeutic drugs and radiation [67]. A robust DNA repair mechanism has 
been linked to increased resistance to cancer chemotherapeutic agents. 
In 2009, BSI-201, or iniparib, became the first DNA repair inhibitor for 
breast cancer to reach a phase III clinical trial [68]. Iniparib blocks a signaling 
enzyme called poly(ADP – ribose) polymerase (PARP1). The PARP1 enzyme 
recognizes and eliminates oxidized DNA bases, which would otherwise 
accumulate and kill cells. Inhibition of Chk1 and Chk2 — protein kinases involved 
in checkpoint control following DNA damage — sensitized brain cancer cells to 
radiotherapy in cell culture [69]. Other DNA repair proteins being studied as drug 
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targets include ATM and ATR kinases, breast cancer susceptibility protein 
(BRCA) proteins, and DNA mismatch repair proteins [68]. 
In the BER pathway, inhibitors of glycosylases have been explored as 
cancer chemotherapy agents. Due to the multiple DNA glycosylases in each cell, 
it is difficult to disrupt BER by inhibiting glycosylases. As the rate limiting 
enzymes in BER, AP endonucleases are very attractive targets for disruption of 
the pathway. Indeed, targeting AP endonucleases has been studied in the 
treatment of cancer. There are currently three compounds known to inhibit the 
human AP endonuclease, APE1: methoxyamine (MX) and two compounds, 7-
nitroindole-2-carboxylic acid (NCA) and Lucanthone [69]. 
Lucanthone, originally identified as a topoisomerase II inhibitor, is 
considered to be a direct inhibitor of APE1's DNA repair activity [69]. Lucanthone 
was extensively used to treat schistosomiasis and shown to be safe from a 
clinical standpoint [70]. Cancer cells treated with lucanthone exhibit a dose-
dependent increase in AP sites due to inhibition of APE1 repair activity. Patients 
with brain metastasis treated in combination with radiation and lucanthone 
showed increased regression of the tumors with the combination as compared to 
radiation alone [70]. The detrimental impact of DNA inhibition on human cells 
needs to be weighed carefully before targeting this pathway in pathogenic 
protozoa such as Toxoplasma or Plasmodium. It is plausible that intracellular 
parasites, being insulted with ROS from the host, rely on DNA repair pathways 
much more than human cells, and therapeutic concentrations that inhibit 
parasites will be significantly lower. In addition, there appear to be nuances in the 
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parasite pathways that could be exploited for therapy. As we will show, the 
Toxoplasma APE1 homologue is remarkably different than its human 
counterpart, and some enzymes, such as TgAPN, are not present in mammals. 
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4. Summary and specific aims 
As mentioned previously, current drug therapies for Toxoplasma infection 
are limited due to toxic side effects [35]. It is therefore necessary to identify new 
drug targets with an increased likelihood of selective toxicity towards the 
parasite. 
DNA repair is likely to serve as a good drug target in Toxoplasma. As an 
obligate intracellular parasite, Toxoplasma is exposed to host cell metabolites 
such as ROS that induce DNA damage [61]. ROS are also produced by immune 
effector cells to kill the parasite. Toxoplasma is also susceptible to respiratory 
burst activity from monocytes responding to Toxoplasma invasion [47]. The rapid 
growth and replication of Toxoplasma can also lead to a high frequency of base 
mismatches during asexual reproduction. In other species, the majority of DNA 
oxidative damage is repaired through the base excision repair (BER) pathway, 
and apurinic/apyrimidinic (AP) endonucleases are the rate limiting enzymes in 
BER. Toxoplasma possesses two different AP endonucleases. We have cloned 
both AP endonucleases in Toxoplasma (termed TgAPN and TgAPE). TgAPE is a 
magnesium-dependent homologue of human APE1 (hAPE1), but TgAPE is 
considerably divergent from hAPE1. TgAPN is a magnesium-independent 
homologue of yeast APN1 endonuclease and is not present in mammals. The 
absence of APN in mammals makes TgAPN particularly attractive to investigate 
as a potential drug target. Preliminary data from Western blot analysis and real-
time PCR suggests that TgAPN is more abundant than TgAPE in the parasite. 
Thus, our hypothesis is: TgAPN is the predominant AP endonuclease in 
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Toxoplasma that is critical for DNA repair and viability. Our research strategy to 
address this hypothesis focuses on the following aims. 
AIM 1: Determine the role of TgAPN in the Toxoplasma response to DNA 
damage. 
To address this aim, we generated a FLAG-tagged TgAPN over-expressor 
parasite. The parasites engineered to over-express TgAPN under a strong 
tubulin promoter were used to determine if there is increased protection against 
DNA-damaging agents such as methyl methanesulfonate (MMS) compared to 
wild-type parasites. Second, we created a TgAPN conditional knockout parasite 
that allows for the regulation of an ectopically expressed TgAPN using a 
tetracycline analogue. Finally, we generated a parasite with the endogenous 
TgAPN protein fused to a destabilization domain. Parasites expressing 
regulatable TgAPN protein were used to determine if loss of TgAPN makes the 
parasites more susceptible to DNA damaging agents. 
AIM 2: Pharmacological inhibition of TgAPN 
No inhibitors of APN1 have been identified to date. As our preliminary data 
suggest that TgAPN is more abundant in the parasite than TgAPE, and TgAPN is 
not present in mammals, we characterized TgAPN inhibitors obtained from a 
high-throughput screen against TgAPN enzyme activity. The most promising 
inhibitors from the high-throughput screen were tested against the parasite in 
vitro to determine inhibition of parasite growth. We also determined the IC50s of 
the compounds using standard parasite growth assays.  
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CHAPTER 2: MATERIALS AND METHODS 
1. Parasite culture and manipulation  
A. Parasite culture and tissue culture 
Toxoplasma gondii tachyzoites were cultured in human foreskin fibroblasts 
(HFF) in Dulbecco Modified Eagle’s Media (Gibco # 21013-024) supplemented 
with 1% heat inactivated fetal bovine serum (Gibco # 16000-044). Flasks were 
maintained in a humidified incubator at 37°C and 5% CO2. Type I RH strain 
parasites were used for all experiments, and were obtained from the AIDS 
Research and Reference Program (Division of AIDS, NIAID, National Institutes of 
Health).  
  HFF host cells (American Tissue Culture Company) were grown to 
confluency before infection with parasites. Host cell media was comprised of 
Dulbecco Modified Eagle’s Media (Gibco # 21013-024) and 10% heat inactivated 
fetal bovine serum (Gibco # 16000-044). All tissue culture was carried out under 
sterile conditions in a laminar flow hood. HFF cells are commonly used for the 
culture of Toxoplasma [76]. HFF cells offer several advantages in the culture of 
Toxoplasma such as: a large contiguous monolayer that allows for multiple 
parasite replication cycles, yielding large parasite titers. The HFF cells also have 
high contact inhibition that ensures a continuous monolayer can be prepared 
long before they need to be used. The confluent HFF cells are resistant to many 
metabolic inhibitors and facilitate drug selection and drug assays. As primary 
host cells, HFF cells provide a more clinically relevant model system than other 
cells. 
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Splitting HFF cells for subsequent passage was done using trypsin 
digestion. The HFF media was aspirated and the monolayer washed with 3 mls 
of PBS before adding of 3 mls of trypsin. The flask is incubated at 37°C for 1 
minute to facilitate trypsin digestion. The flask was then agitated to ensure more 
complete dislodging from the flask surface. Trypsin activity was neutralized by 
addition of HFF media before being passed into new sterile flasks. 
Parasite and host cell tissue culture were checked monthly for 
Mycoplasma contamination. Mycoplasma is a common tissue culture 
contaminant and can affect the outcome of experiments. Mycoplasma is a 
bacteria genus that lacks a cell wall and is resistant to many types of antibacterial 
agents. Mycoplasma can be free living or saprophytic in decaying matter. The 
extremely small size of the bacteria makes detection by light microscopy difficult. 
It has been estimated that at least 11 to 15% of U.S. laboratory cells cultures are 
contaminated with Mycoplasma [72]. Cultures were tested for the presence of 
Mycoplasma using the MycoAlert Mycoplasma Detection kit (Lonza # LT07-318). 
The MycoAlert kit detects Mycoplasma through activity of Mycoplasma enzymes. 
The viable Mycoplasma cells are lysed and the enzymes react with the MycoAlert 
substrate catalyzing the conversion of ADP to ATP. This increase in ATP can be 
detected using a bioluminescent reaction quantified using a luminometer. 
Although Mycoplasma was not detected in the cultures, contamination can be 
removed from tissue culture. Passing the parasites through a mouse will 
eliminate the Mycoplasma through the mouse immune system. Toxoplasma 
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cultures contaminated with Mycoplasma can also be treated with Mycoplasma 
Removal Agent (MP Biomedicals # 093050044), an inhibitor of bacterial gyrase. 
B. Freezing and thawing  
Parasites were frozen for storage in liquid nitrogen. To prepare a frozen stock of 
parasites, they were grown to the point where about 80% of the HFF cell 
monolayer was disrupted by lysis. The remaining infected cells were harvested 
by scraping with a sterile spatula (Fisher # 08-773-2). Free parasites and infected 
host cells from the flask were pelleted by centrifugation at 8,000 g at 4°C for 10 
minutes. The pellet was resuspended in 1 ml FBS with 10% DMSO. The mixture 
was aliquated into (1 ml) cryovials (Cryotube # 368632) and frozen at -80°C in a 
Styrofoam container before being moved into the liquid nitrogen tank. Parasites 
are thawed by immediately placing the frozen cryovial in a 37°C water bath. 
Once thawed, the cryovials are cleaned with 70% ethanol to avoid contamination, 
and then inoculated onto a new HFF cell monolayer. The parasite media was 
changed 24 hours post-infection. 
C. Purification of parasites from HFF cells 
 Purification of parasites helps remove host cell debris that might hinder 
downstream applications. To ensure safety and sterility, all steps involving 
parasites are carried out in a laminar flow hood. 
 The first step of parasite purification involves scraping the infected HFF 
cells with a spatula. The material was then placed into a syringe (Fisher # 14-
840-52) attached to a 3.0 µM filter (Whatman # 110612). The media and 
parasites are forced through the filter into an awaiting collection tube by 
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compressing the plunger. Toxoplasma tachyzoites are ~2 x 6 microns and will 
pass through the filter while the majority of host cell debris remains behind [76]. 
The filtered parasites are then centrifuged at 8,000g for 10 minutes. Filter-purified 
parasite pellets are washed through resuspension in 15 ml sterile PBS for 
another round of centrifugation. The parasites are washed in PBS two more 
times before used in downstream applications. 
D. Toxoplasma lysate preparation 
Toxoplasma protein lysate was made in RIPA buffer (50 mM Tris; 150 mM 
NaCl; 1% NP40; 0.5% Na-deoxycholate) unless specified otherwise. Also 
included was the mammalian protease inhibitor cocktail (Sigma # p8340), used 
as per manufacturers suggestion (1:100). After the parasites are purified as 
described above, the pellet was resuspended in RIPA buffer containing protease 
inhibitors. The parasites are then sonicated three times on ice for 15 second 
bursts interspersed with 30 second recovery period on ice. The sonicated lysate 
was centrifuged at 13,000g for 10 minutes at 4°C to pellet cell debris, insoluble 
protein and DNA. The supernatant that contains soluble protein was collected 
using a pipette.  
E. Quantification of parasites 
Quantification of parasites was achieved using a hemocytometer (Hauser) 
(Figure 3). The parasites are first filter-purified as described above and 10 µl was 
loaded into each counting chamber. The hemocytometer was placed under a 
Leica DM IL inverted microscope and the parasite counted at (100X). Two 
independent counts are made for each sample i.e. the hemocytometer was 
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cleaned and fresh sample was loaded and counted. The average of each of the 
counts was used to calculate the number of parasites in the sample. The final 
average was multiplied by 25 because of the 25 squares of the grid. The result 
was multiplied by 10,000 because of the volume of the grid in the hemocytometer 
was approximately 1 microliter. 
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Figure 3: Counting grid of hemocytometer. The highlighted numbers represent 
the 5 individual squares counted for each replicate.   
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F. Transfection of parasites 
 Transfections were performed to introduce recombinant DNA into the 
parasites to make transgenic lines. The primary transgenic parasites generated 
during this work include TgAPE and TgAPE over-expressor parasite lines, a 
TgAPN conditional knockout, and the Shield-1 regulated TgAPN. 
25 µg of plasmid DNA was used for each transfection. Plasmid DNA was 
propagated in E. coli bacteria and purified by maxiprep (Zymo Research # 
ZRC163686). Purified plasmid DNA was linearized by restriction digest and 
precipitated for transfection. The DNA was first extracted using phenol- 
chloroform to remove salts and restriction enzymes. An equal amount of phenol-
chloroform and sample were mixed together by vigorous vortexing. The mixture 
was centrifuged at 13,000 rpm for 2 minutes to separate the aqueous and 
organic phases. The upper aqueous phase that contains the DNA was removed 
by pipetting. The DNA was precipitated by adding 2.5X cold 100% ethanol and 
0.1X 3M NaOAc, pH 5.2 followed by mixing and incubation at 80°C for at 30 
minutes. The sterile plasmid DNA was dissolved in 100 µM cytomix (2 mM 
EDTA, 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES, 5 
mM MgCl2 6H2O; pH 7.6) freshly supplemented with 5 mM of glutathione and 2 
mM of ATP [73]. 
Parasites were filter-purified and washed in cytomix three times before 
counting on a hemocytometer. 2X107 parasites in 300 µl cytomix were used for 
each transfection. The parasites and the plasmid DNA were mixed together by 
pipetting and transferred to a 2 mM gap electroporation cuvette (Fisher # 14-955-
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128). Electroporation was done at the following settings: voltage=1500, 
resistance=25 ohms, capacity=25 µF. After electroporation, the cuvette was 
placed in the laminar flow hood for 15 minutes to allow the parasites to recover. 
The transfected parasites were passed onto a fresh monolayer with parasite 
media and allowed to replicate under standard culture conditions. For generation 
of clones, the transfected parasites were split into four flasks to reduce the 
chances of getting ―sister‖ parasites. Selection in the appropriate drug was 
initiated following the first round of lysis post-transfection. Three rounds of drug 
selection were performed before the parasites were cloned. The drugs used for 
each transfection are shown in Table I. 
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Table I: Drugs used to select transgenic parasites. 
Selection Agent  Concentration  Vehicle  Additional 
Information  
Mycophenolic acid 
(MPA)  
25 μg/ml  100% ethanol  For RHΔHX 
parasites when 
HXGPRT gene is 
utilized for 
selection  
Must include XAN 
as a supplement  
Xanthine (XAN)  50 μg/ml  fresh 0.5M KOH  Used in 
combination with 
MPA  
6-thioxanthine 
(6TX)  
320 μg/ml  fresh 0.5M KOH  For RHΔHX 
parasites prior to 
transfection to 
verify strain  
Chloramphenicol 
(CAM)  
20 μM  100% ethanol  CAT gene utilized 
for selection  
Pyrimethamine 
(PYR)  
1 μM  70% ethanol   Mutant 
pyrimethamine 
resistant DHFR 
gene utilized for 
selection  
 
 45 
 
G. Cloning by limiting dilution 
 After three rounds of drug selection, parasites were cloned by limiting 
dilution to obtain homogenous populations. After determining the count, the 
parasites are diluted in media to yield approximately 1 parasite per well in a 96-
well plate containing confluent HFF cells. Drug selection continues throughout 
the limiting dilution process. After approximately 10 days, plaques (areas of lysis) 
will appear in some wells. Parasites arising from single plaques were picked and 
inoculated into new HFF cells for expansion and subsequent analysis. 
H. Parasite growth assays 
 Parasite growth assays were used to evaluate the viability of parasites 
following treatment with DNA damaging agents or TgAPN inhibitors. Four 
established Toxoplasma viability assays were used:  
Plaque assay 
 Plaque assays were performed in 24-well plates of confluent HFF cells 
based on standard protocols [76]. For each experiment a duplicate 24-well plate 
was used. One of the plates was used as a reference plate to examine the 
progression of the experiment during the experiment (typically lasting 7 days). 
The other plate (experimental plate) was not to be moved for the duration of the 
experiment to prevent parasites from being moved and forming secondary 
plaques. 1,000 parasites are infected into each well and infected monolayers are 
grown for 7 days (judging by progress of reference plate, which was viewed 
throughout the experiment) at 37°C and 5% CO2. Each experimental sample was 
done in triplicate, taking up three wells in the plate. At the end of the 7 days or 
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when the reference plate wells indicate the desired plaque sizes, monolayers are 
fixed in ice cold (-20°C) methanol for 5 minutes after the culture media was 
aspirated. The methanol was aspirated and the monolayers are allowed to dry at 
room temperature. Crystal violet solution (1 µg/ml crystal violet, 25% ethanol, 1% 
ammonium oxalate) was used to stain the dried monolayers to facilitate 
visualization and counting of the plaques. Plaques are counted for each sample 
and the average of the triplicate scored as the plaque number. 
B1 assay 
 The B1 assay is a PCR-based assay that amplifies the B1 region of the 
parasite genome [74,75]. This particular sequence is chosen for amplification 
because it is parasite-specific, i.e. the primers do not amplify host cell DNA. 
1,000 parasites are infected onto a monolayer of HFF cells in a 24-well plate. 
The standard duration for the B1 assay is 5 days, unless stipulated otherwise. At 
the end of the fifth day, the samples are collected by aspirating the media and 
adding 400 µl of lysis solution (Qiagen, DNeasy kit (200 µl AL, 200 µl PBS, 20 µl 
proteinase K)) for 1 minute. Infected cells were dislodged by scraping and 
transferred into a collection tube. The lysate solution was heated for 10 minutes 
at 56°C. The heated lysate was mixed with 200 µl of 100% ethanol by vortexing. 
The entire mixture was transferred to a DNeasy spin column and centrifuged for 
1 minute at 8,000g to bind the DNA to the column matrix. 500 µl of buffer AW1 
was added to the column and centrifuged for 1 minute at 8,000g. 500 µl of buffer 
AW2 was added to the column and centrifuged for 3 minutes at 13,000g. 100 µl 
of elution buffer was added to the column and the samples were collected after 1 
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minute centrifugation at 8,000g. The eluted samples were heated to 95°C for 5 
minutes to heat-inactivate proteinase K. The samples were diluted by 1:10 in 
distilled water before proceeding to the real-time PCR phase of the experiment. 
The real-time PCR master mix is as follows: 
12.5 µl SYBR green mix (ABI # 4364344) 
1.0 µl B1 forward primer (GGAGGACTGGCAACCTGGTGTCG) 
1.0 µl B1 reverse primer (TTGTTTCACCCGGACCGTTTAGCAG) 
9.5 µl Water distilled water 
1.0 µl sample 
24 µl of the master mix was pipetted into each sample well of a MicroAmp 96well 
plate (Applied Biosystems # 4346906) followed by 1 µl of sample. All samples 
were set up in triplicate. Standards of known parasite number (10,000, 5,000, 
2,500 and 1,250 parasites) were also included in the setup. The plate was 
covered by an adhesive optical membrane (Applied Biosystems # 401194). The 
real-time PCR was performed on a StepOnePlus (Applied Biosystems) machine. 
The amplification signal of the samples was quantified using the signal of the 
known standards. 
 Doubling assay 
Parasite doubling assays were performed in T-25 cm2 flasks containing 
confluent HFF monolayers based on previously published methods [76]. 1X107 
parasites were inoculated into the flask and parasites that did not infect in the 
first 4 hours are washed off by changing the media. The flasks were incubated at 
37°C in a humidified incubator with 5% CO2. Parasites within 50 random 
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vacuoles were counted at the indicated time points. A Leica DM IL inverted 
microscope was used to count the parasites at 100X [76]. 
 Monolayer disruption assay 
 HFF monolayer disruption assays were used to assess if compounds from 
the TgAPN inhibitor screen had activity against Toxoplasma tachyzoites in vitro. 
3,000 parasites were added to each well of a 96-well plate containing confluent 
monolayers of HFF cells. A serial dilution (0.05 µM to 100 µM) of each inhibitor 
(or vehicle) was added to a row of infected wells. Assay plates were analyzed 
every 12 hours. The 96-well plates were incubated at 37°C in a humidified 
incubator with 5% CO2 for the duration of the experiment, which typically lasts 
about 5 days.  
2. Molecular biology and biochemical techniques 
A. Cloning of TgAPE and TgAPN 
A search of the Toxoplasma genome web site (ToxoDB.org) revealed that 
accession number TGGT1_098640/35.m00892 (chromosome XI) is a homologue 
of human APE1 (hAPE1, ExoIII class) and TGGT1_034710/80.m00015 
(chromosome IX) a homologue of yeast APN1 (EndoIV class). The TgAPE and 
TgAPN open reading frames were amplified from an RH strain tachyzoite cDNA 
library. 5’- and 3’-rapid amplification of cDNA ends (RACE) was performed with 
the GeneRacer™ kit (Invitrogen # L1500-01) using tachyzoite mRNA as a 
template for reverse transcription (RT) with the provided random primers or oligo 
dT primer. RT-PCRs were performed using the SuperScript™ One-Step RT-PCR 
kit (Invitrogen # 45-0167) following manufacturer’s instructions. Nested PCRs 
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were performed with the RACE to determine TgAPE and TgAPN untranslated 
regions (UTRs). TgAPN 5’ RACE was performed using primer 5’-
TTGACACTCGAGTGCTTCGCGTCC as the parental gene specific primer and 
5’-TCCCACCCGCTTTTGTGTCTAATGT as the nested gene specific primer. 
TgAPE 5’ RACE was done using primer 5’-TAGTTGCTCGATGAGGTCCCTCAG 
as the parental gene specific primer and 5’-CCTCTTCTCCCTGTGCTGAGTTCA 
as the nested gene specific primer. GeneRacer™ 5’ primers were used as the 
forward primers in the initial and nested PCR reactions. TgAPN 3’ RACE was 
done using primer 5’-CGATGCATATCAACGATTCTAAGGCT as the parental 
gene specific primer and 5’-GAAGCGGCCTGGACAGACACGA as the nested 
gene specific primer. TgAPE 3’ RACE was done using primer 5’-
CCATATCGTGTTGACGGAGACGCT as the parental gene specific primer and 
5’-CTCGTGAGAATTTGCGGAGCTGGA as the nested gene specific primer. The 
GeneRacer™ 3’ primers were used as the reverse primers in the initial and 
nested PCR reactions. 
B. Purification of recombinant TgAPE and TgAPN 
Recombinant TgAPE and TgAPN were produced in the laboratory of Dr. 
Millie Georgiadis (IUSM). An expression vector for TgAPE was constructed in 
pET28a including an N-terminal cleavable hexa-histidine tag using NdeI and NotI 
restriction sites. Following transformation into the Rosetta E. coli strain, a 1 liter 
culture was induced at 37˚C for 4 hrs, after which cells were pelleted and stored 
at -80°C prior to purification. The cell pellet was resuspended in 25 ml of lysis 
buffer, Buffer A (50 mM Na phosphate pH 7.8, 0.3M NaCl) with 10 mM imidazole, 
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sonicated, and centrifuged at 35K for 35 min in an ultracentrifuge. The crude 
extract was incubated with 1 ml of a Ni-NTA agarose slurry for 45 minutes at 4°C, 
placed in a column, washed with 10 ml of wash Buffer A with 20 mM imidazole 
and eluted with 2 x 1.5 ml of elution buffer, Buffer A with 250 mM imidazole. 
Fractions were diluted to 0.05M NaCl with Buffer B (50 mM HEPES pH 7.5, 1 
mM DTT) and applied to a Q-Sepharose column using an AKTA FPLC system. 
The protein was then eluted from the Q-Sepharose column using a NaCl gradient 
(0.05M NaCl to 1M NaCl). The fractions containing TgAPE were combined and 
digested overnight with thrombin in order to remove the N-terminal hexa-His 
affinity tag. The sample was then diluted to a final salt concentration of 0.05M 
NaCl with Buffer B and subjected to a NaCl gradient separation on the Q-
Sepharose column as before. Fractions including TgAPE were combined, 
concentrated, and stored at -80°C. The purified sample is greater than 95% pure 
as judged by SDS-PAGE analysis. 
An expression vector for TgAPN was constructed in pET15b using NdeI 
and BamHI. Expression and purification were similar to that described for TgAPE 
with the same buffers used for Ni-NTA affinity purification followed by S-
Sepharose ion-exchange chromatography. The fractions containing TgAPN from 
the Ni-NTA purification were pooled, diluted in 50 mM HEPES pH 7.0, 1 mM 
DTT, and eluted using a NaCl gradient 0.05-1.0 M in the same buffer. Fractions 
including TgAPN were combined, concentrated, and stored at -80°C. The purified 
sample was approximately 90% pure. 
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C. DNA repair assays 
 Gel based DNA repair assays were carried out in the laboratory of Dr. 
Mark Kelley (IUSM). To test if the recombinant TgAPE and TgAPN exhibited AP 
endonuclease activity, we performed DNA repair assays using increasing 
concentration of purified recombinant protein. The DNA repair assay uses 5-
hexachloro-fluorescein phosphoramidite (HEX)-labeled terahydrofurayl (THF) 
oligo. The oligonucleotide is 26 bp long and contains a THF, an abasic site 
analogue, in the middle. Upon DNA repair the AP endonuclease cleaves the 
oligonucleotide at the synthetic AP site (THF) yielding a 13mer fragment. The 
reaction products can then be visualized using a 20% polyacrylamide gel 
Increasing amounts of recombinant TgAPE were incubated in buffer A (50 mM 
HEPES, 50 mM KCl, 10 mM MgCl2,1 µg/ml BSA, 0.05% Triton X-100, pH 7.5). 
Increasing amounts of recombinant TgAPN were incubated in buffer B (50 mM 
HEPES, 50 mM KCl, 20 mM EDTA,1 µg/ml BSA, 0.05% Triton X-100, pH 7.5). All 
reactions contained 1 mM DTT and 0.05 pmol HEX-TEF oligonucleotide in a total 
of 10 ml and were incubated at 37ºC for 15 minutes (Figure 4). 
 Fluorescent based DNA repair assays and enzyme kinetics were done in 
collaboration with Dr. Millie Georgiadis. AP endonuclease activity was measured 
in a fluorescent-based kinetic assay using a duplex DNA substrate containing a 
tetrahydrofuran abasic site mimic as the substrate. The oligonucleotides were 
diluted in water to a final concentration of 100 µM and annealed in a 4:5 ratio of 
fluorescein vs. dabcyl labeled oligonucleotides. Release of the fluorescein 
labeled oligonucleotide following cleavage at the abasic site by an AP 
 52 
 
endonuclease is achieved by thermal denaturation at 37°C and followed in the 
kinetic mode on a Tecan Ultra 384 instrument using an excitation wavelength of 
485 nm and emission of 535 nm. TgAPN was assayed in 50 mM MOPS 7.5, 50 
mM NaCl, and 0.8% DMSO. An optimal concentration of 4 nM TgAPN was 
determined by varying the enzyme concentration with fixed substrate 
concentration of 25 nM. The substrate was then varied from 0 to 75 nM in order 
to determine Vmax and Km values for this enzyme. Similarly, 0.05 nM TgAPE was 
used with substrate concentrations of 0 to 75 nM in 50 mM MOPS 7.5, 50 mM 
NaCl, 1 mM MgCl2, and 0.8% DMSO. DMSO was included in the assay in 
preparation for screening of small molecule inhibitors dissolved in 0.8% DMSO 
and found not to affect the activity of the enzyme. Kinetic parameters were 
calculated from the average of quadruplicate measurements for each substrate 
concentration using the Enzyme Kinetics module in SigmaPlot (SigmaPlot 11.2). 
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Figure 4: Schematic of a gel based DNA repair assay. A HEX labeled 
oligonucleotide with an abasic site mimic is cleaved in the presence of protein or 
cell extract with AP endonuclease activity. The cleavage product can be 
visualized after being denatured and resolved in a polyacrylamide gel. 5-
hexachloro-fluorescein phosphoramidite (HEX). F=Terahydrofurayl (THF). 
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D. Generation of antisera recognizing TgAPE and TgAPN 
 Purified recombinant TgAPE and TgAPN (with N-terminal poly-his tag 
removed) were injected into rabbits for production of polyclonal antisera at 
Quality Controlled Biochemicals (Hopkinton, MA). Two rabbits were used for 
each of the proteins of interest. A pre-bleed was done prior to the injection of the 
rabbits with the antigen. Five other bleeds including a terminal bleed were done 
after injection with the antigen. 
 Western blot analysis of the raw serum collected from inoculated rabbits 
was performed to access reactivity against recombinant TgAPE or TgAPN 
protein and native Toxoplasma protein in parasite lysate. After establishing that 
the raw antisera recognized the respective recombinant and native protein using 
Western blot, the antisera were prepared for affinity purification. 
The first stage of the affinity purification involves preparation of the 
purification column. The matrix used for the purification was the Affi-gel system 
(Biorad). Two matrices were used based on the isoelectric (PI) point of the 
respective recombinant proteins (TgAPE PI 6.53, TgAPN PI 9.04). Recombinant 
TgAPE was immobilized on Affi-gel 15 and recombinant TgAPN was immobilized 
on Affi-gel 10. 2 mg of each recombinant enzyme was dialyzed in 0.1 M 
phosphate buffer pH 7 or pH 8 for Affi-gel 15 and 10, respectively. The 
recombinant proteins (referred to as antigens) and beads were incubated 
together at 4°C overnight. The next day the matrix was washed with 10 ml 10 
mM Tris pH 7.5 and 10 ml 100 mM glycine pH 3 to remove unbound antigen. 
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 The next step of affinity purification involves purifying the raw serum over 
the column. The serum (10 ml) was dialyzed against (1,000 ml) 5 mM sodium 
phosphate pH 6.5 overnight. The dialyzed serum was pre-cleared over a DEAE 
matrix (Sigma # DF-100). After pre-clearing, the serum was rocked with the 
matrix overnight at 4°C. The matrix was then washed with 10 mM Tris by 
resuspending and centrifugation for 1 minute at 8,000 rpm. The antibodies are 
eluted with 10 ml 100 mM glycine pH 3. The eluted antibody solution was further 
concentrated using 30kD Amicon centrifugal concentrators (Amicon # 
UFC801024) to a volume of 2 ml. The affinity-pure antibodies were then 
quantified using the Pierce BCA protein assay kit (Thermo scientific # 23225). 
The affinity pure antibodies were evaluated by Western blot probing recombinant 
protein and Toxoplasma protein lysate. 
E. Generation of parasites over-expressing TgAPE and TgAPN 
FLAG-tagged TgAPE and TgAPN were ligated into the ptubFLAG::HX 
expression vector using the NdeI and AvrII restriction sites (Bhatti and Sullivan, 
2005). FLAGAPN was amplified using primers (sense) 5’-
TCGATCGCATATGAAAATGGACTACAAGGACGACGACGACAAGACGGCTGC
AGCGTCCCTAAGAAAAACCAAGG and (antisense) 5’-
TCGATCGCCTAGGTCACTCTTCGATGATGAATTTGTACATCATCTCC, where 
the underscored sequences represent the NdeI and AvrII restriction sites, 
respectively, and FLAG sequence is italicized. FLAGAPE was amplified using 
primers (sense) 5’-
ATCATATGAAAATGGACTACAAGGACGACGACGACAAGTCTGTTCACAGAG
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CAGTGAACTCA and (antisense) 5’-
ATCGAACCTAGGTCAACTGGAGGCCTGGACGTTTCGCG. 
The parasite strain used to generate the over-expressor parasite lines is 
RHΔHX. This is a parasite in which the HXGPRT (hypoxanthine-xanthine-
guanine phosphoribosyltransferase) enzyme has been deleted [89]. Prior to any 
experiment, the RHΔHX parasites are selected using 6-thioxanthine (Acros 
organics # 241720010). 6-thioxanthine is a subversive substrate of HXGPRT as 
it is metabolized into a toxic metabolite. Parasites complemented with a plasmid 
containing HXGPRT can be selected by mycophenolic acid (Sigma # M3536) 
and xanthine (Sigma # X-4002) (Figure 5) because mycophenolic acid inhibits 
inosine monophosphate dehydrogenase (IMPDH) and parasites can only 
synthesize guanine nucleotides through the enzymatic action of HXGPRT in the 
presence of xanthine [77]. 
The N-terminal FLAG-tagged TgAPE and TgAPN constructs were 
linearized with NotI and electroporated into RHΔHX tachyzoites (Figure 6). 
Transgenic parasites were selected in mycophenolic acid (25 µg/ ml) and 
xanthine (50 µg/ ml) and cloned by limiting dilution. The individual clones were 
confirmed by IFA and Western blot. Anti-TgAPE and anti-TgAPN antibodies at 
1:10,000 were used to determine if the transgenic clones were indeed over-
expressing TgAPE or TgAPN.  
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Figure 5: Toxoplasma purine synthesis pathway. Toxoplasma depends on the 
host cell for its purine requirements. Knocking out HXGPRT (hypoxanthine-
xanthine-guanine phosphoribosyltransferase) prevents the parasite from utilizing 
guanine or xanthine to produce GTP. The parasite can overcome the loss of 
HXGPRT through the action of inosine-monophosphate dehydrogenase 
(IMPDH). Inhibition of IMPDH by addition of MPA (mycophenolic acid) results in 
the parasites being dependent on HXGPRT and xanthine for the production of 
guanine nucleotides. Therefore, the addition of MPA to RHΔHX parasites results 
in death, unless the parasites incorporated HXGPRT through transfection. 
RHΔHX parasites are resistant to 6TX (6-thioxanthine) due to the lack of 
HXGPRT. 6TX is metabolized by HXGPRT into a toxic metabolite that kills the 
parasite. 
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Figure 6: FLAG-tagged TgAPE and TgAPN constructs. Both TgAPE and TgAPN 
open reading frames were ligated into the ptubFLAG::HX expression vector that 
utilizes a strong tubulin promoter. An N-terminal FLAG tag was used on each 
construct. A) FLAG tagged TgAPN. B) FLAG-tagged TgAPE. The ptubFLAG::HX 
expression vector was made in a Bluescript vector backbone and contains a 
HXGPRT minigene. 
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F. Generation of the TgAPN conditional knockout 
 The TgAPN open reading frame with a C-terminal HA tag and an N-
terminal FLAG tag was inserted into plasmids containing modified SAG1 and 
SAG4 promoters engineered to be regulated in a tetracycline (Tet)-off manner 
[78] (Figure 7). These plasmids also contain a minigene encoding 
chloramphenicol resistance for selection purposes [79]. The sites used in both 
the modified tet-based SAG1 and SAG4 plasmids were NsiI and PacI. The 
forward primer 5’-
ATACCATCCTGCAGGAAAATGGCGGAGCAGAAGCTCATCTCTGAGGAGGAC
CTCACGGCTGCAGCGTCCCTAAGAAAAACC contained a SbfI restriction site 
that generates compatible ends with NsiI. The HA tag is in italics. The reverse 
primer was 5’- 
ATACCATTTAATTAATCACTTGTCGTCGTCGTCCTTGTAGTCCTCTTCGATGA
ATTTGTACATCATCTCC. The PacI site is underlined, while the FLAG sequence 
is in italics. 25 µg of vector was linearized using NotI and transfected into TATi 
parasites [78]. TATi parasites are engineered to express a transactivator protein 
that binds the modified SAG1 and SAG4 promoters to induce expression of the 
gene of interest, in this case TgAPN. In the presence of anhydrous tetracycline 
(ATc, Sigma # 37919-100MG-R) the transactivator is bound to the drug and 
cannot associate with the promoter elements. Following the first host cell lysis 
after electroporation, 20 µM chloramphenicol (Sigma # C0378) was added to 
select for the presence of the SAG1 or SAG4 plasmid. Three rounds of drug 
selection were performed before cloning by limiting dilution. Selected parasites 
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were evaluated using IFA and Western blot using FLAG antibody and protein 
specific antibodies. 
A pDHFR plasmid containing a minigene encoding resistance to 
pyrimethamine was used to generate a knockout vector for TgAPN. The pDHFR 
vector encodes mutated dihydrofolate reductase, which confers resistance to 
pyrimethamine [80]. Two 3.5 kb genomic sequences flanking the TgAPN coding 
region were amplified from RH DNA using the Qiagen® LongRange PCR kit. 
HindIII and NotI sites were used to insert the 5’ and 3’ genomic flanking 
sequences into the vector, respectively. The forward primer for the 5’ flanking 
sequence was 5’-
GCAGTGAAGCTTCCGTCGCCTCTCGCGATGTTTTCCCGCCAGTCG and 
reverse primer was 5’- 
GCAGTGAAGCTTCGTAACCGTATCATGACATAGCACCACGAATCCGC. The 
HindIII sites are underlined. The forward primer of the 3’ flanking sequence was 
5’- 
GCAGTGGCGGCCGCGCTCGTTGAGGGGAGCCACGGCGCGGCAGACTTGG 
and the reverse primer was 5’- 
GCAGTGGCGGCCGCCGCAGGAGACTGGGGGTCCATTTCTACGCCATGCC. 
The NotI sites are underlined. Clones expressing ectopic, ATc-regulatable 
TgAPN driven by modified SAG1 or SAG4 promoters were transfected with 25 µg 
of the knockout vector after it was linearized using ScaI. 1 µM of pyrimethamine 
was included in cultures following the first lysis. Three rounds of drug selection 
were performed before cloning by limiting dilution. Clonal populations were 
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evaluated using PCR and Western blot. PCR using intron spanning primers 
determined the disruption of the TgAPN genomic locus and Western blot 
determined the loss of the native TgAPN protein. 
 
 
 
Figure 7: TgAPN conditional knockout constructs. A) The ectopic copy of TgAPN 
was cloned into a SAG1 vector with a Tet-regulated promoter. The ectopic 
TgAPN was HA and FLAG-tagged. Chloramphenical acetyltransferase (CAT) 
conferred resistance to chloramphenical. B) TgAPN flanking sequence (UTR) 
were cloned into a pDHFR vector with a mutant DHFR denoted by an asterisk (*) 
that confers protection to pyrimethamine. The TgAPN genomic locus is replaced 
by the construct by homologous recombination. 
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G. Generation of parasites expressing Shield-1 regulatable TgAPN protein 
The 3’ end of the endogenous TgAPN genomic locus was tagged with two 
hemagglutinin (HA) epitopes and a destabilization domain (DD) (Figure 8). 1,504 
bp of the 3’ end of the TgAPN genomic locus was amplified minus the stop codon 
using Phusion® High-Fidelity DNA Polymerase (New England Biolabs) and the 
following primers: (sense) 5’-
TACTTCCAATCCAATTTAATGCCCTCCACAGTGTACAGACAGTTCCTCTAGG
C and (antisense) 5’-
TCCTCCACTTCCAATTTTAGCCTCTTCGATGAATTTGTACATCATCTCCG. The 
amplified product was cloned into the LIC-HA2X-DD-DHFR-TS vector as 
described [82]. The completed plasmid was linearized with BlpI and transfected 
into ΔKu80 RH strain parasites, which are more amenable to homologous 
recombination due to the reduced occurrence of non-homologous end joining 
[81,82]. 1 µM pyrimethamine was added to cultures after the first lysis to select 
for stable transgenics. Three rounds of drug selection were performed before 
cloning by limiting dilution. Pyrimethamine-resistant clones were examined for 
the loss of TgAPN-DD protein in the absence of Shield-1. Selected parasites 
were evaluated using PCR and Western blot using intron spanning primers and 
TgAPN antibody. 0.2 µM of Shield-1 was used to stabilize TgAPN-DD protein. 
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Figure 8: Endogenously tagging TgAPN with HA and the destabilizing domain. 
1.5 Kb of the C-terminal end of TgAPN was amplified and cloned into the LIC-
HA2X-DD-DHFR*-TS. Through homologous recombination the DD was tagged 
onto the C-terminal of the TgAPN gene 
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H. Immunofluorescence assays 
HFFs grown in 12-well plates containing glass coverslips were used for 
immunofluorescence assays (IFAs). The host cell media was aspirated and 
replaced with parasite media. Parasites to be assayed were infected onto 
coverslips containing HFF monolayers. 24 hrs post-infection, the media is 
aspirated and the monolayer washed 3 times with sterile PBS before fixation with 
1 ml of 3% paraformaldehyde for 15 min at room temperature. The infected cells 
were permeablized with 0.2% Triton X-100 in PBS for 10 min and blocked in 3% 
BSA (fraction V, OmniPur # 2910) in PBS for 30 min. Antibodies used in IFAs are 
represented in Table II. DNA intercalator 4’, 6-diamidino-2-phenylindole (DAPI, 
Invitrogen # D3571) was applied at a concentration of 0.3 µM for 5 min as a co-
stain to visualize nuclei. Secondary antibodies included Alexa Fluor 488 and 594 
(Molecular probe) at 1:2,000 diluted in 3% BSA. Coverslips were prepared for 
viewing using 5 µl mounting media (50% glycerol containing 48 µg/ml Mowiol 
(Calbiochem # 81381) and 10 µg/ml DABCO (Sigma # 10981) to reduce 
photobleaching). Coverslips were mounted on glass slides to view using a Leica 
DMLB fluorescent microscope at 100X with a HCX Plan Apo oil immersion 
objective. Images were captured with a monochrome SPOT-RTSE camera and 
Spot Advance software (version 4.6). Images obtained are colored using Adobe 
Photoshop 7.0. 
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Table II: Primary and secondary antibodies used in IFAs.  
Antibody Description  Source  Dilution  
Primary Antibodies  
Anti-FLAG  
mouse, monoclonal  
Sigma # F1804  1:5,000  
Anti-HA (clone 3F10)  
rat, monoclonal  
Roche # 11867423001  
 
1:1,000  
Anti-TgAPE 
rabbit, polyclonal 
Custom 1:1,000 
Anti-TgAPN 
rabbit, polyclonal 
Custom 1:1,0000 
Secondary Antibodies  
Alexa Fluor® 488 anti-rat, 
IgG  
(from goat)  
Molecular Probes # A-
11006  
 
1:2,000  
Alexa Fluor® 488 anti-
mouse, IgG 
(from goat)  
Molecular Probes # A-
11017  
 
1:2,000  
Alexa Fluor® 488 anti-
rabbit, IgG  
(from goat)  
Molecular Probes # A-
11070  
 
1:2,000  
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Alexa Fluor® 594 anti-
mouse, IgG  
(from goat)  
Molecular Probes # A-
11072  
 
1:2,000 
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I. Immunoblotting  
Affinity-purified antisera recognizing TgAPE and TgAPN were diluted in 
Tris-buffered saline tween (TBST) to a final concentration of 1:10,000. Additional 
antibodies used in this study included: anti-FLAG antibody (Sigma F1804) at 
1:5000 and HA antibody (Sigma) at 1:2,000. Parasite protein lysates were made 
as described previously (section I of materials and methods). The protein lysates 
were reduced in 5% beta-mercaptoethanol and Nupage (Invitrogen # NP0007) 
sample buffer by heating at 95°C for 10 minutes. Reduced samples were loaded 
into 4-12% pre-cast SDS-PAGE gels (Invitrogen # NP0335) and run on a Biorad 
gel system at 200 volts for 50 minutes. After transfer, nitrocellulose membranes 
were blocked in 3% BSA for 2 hrs prior to being probed with the respective 
antibodies for two hours. Horseradish peroxidase conjugated secondary antibody 
(GE Health Care) was used as a secondary antibody at a dilution of 1:5,000. The 
signal was detected using an ECL chemiluminescent system (Thermo Scientific). 
Table III shows the antibodies used in Western blot. 
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Table III: Primary and secondary antibodies used in Western blot. 
Antibody Description Source Dilution 
Primary Antibodies 
Anti-FLAG 
mouse, monoclonal 
Sigma # F1804 1:5,000 
Anti-HA (clone 3F10) 
rat, monoclonal 
Roche # 11867423001 
 
1:3,000 
Anti-tubulin 
rabbit, polyclonal 
Custom 1:5,000 
Anti-TgAPE 
rabbit, polyclonal 
Custom 1:10,000 
Anti-TgAPN 
rabbit, polyclonal 
Custom 1:10,000 
Secondary Antibodies 
ECL rat IgG, HRP-linked 
(from goat) 
GE Healthcare # NA935 1:5,000 
ECL mouse IgG, HRP-
linked 
(from goat) 
GE Healthcare # NA931 1:5,000 
ECL rabbit IgG HRP-
linked 
(from goat) 
GE Healthcare # NA934 1:5,000 
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J. General PCR protocol and agarose gel electrophoresis 
 All primers used in these studies were obtained from Invitrogen in 
lyophilized state. Primers were resuspended to concentration of 100 µM in water 
distilled water. Only plugged tips were used in handling PCR reagents at a 
designated PCR station to minimize contamination. Reactions were set up on ice 
to maintain the integrity of the reagents. Phusion® High-Fidelity DNA polymerase 
(New England Biolabs # F530S) was used for amplification unless stated 
otherwise. PCRs were set up in 50 µl volumes in thin walled 0.5 µl tubes (Fisher 
# AB-0350). The PCR was performer using an Eppendorf thermocycler 
(Eppendorf, Mastercycler). The general PCR set up was as follows: 
1. 98°C for 30 seconds 
2. 98°C for 10 seconds 
3. 60°C for 30 seconds 
4. 72°C for 60 seconds 
Repeat steps 2 to 4  
5. 72°C for 10 minutes 
6. 4°C holding temperature 
PCR samples were analyzed using agarose gel electrophoresis. 1% agarose 
gels containing 0.5 µg/ml ethidium bromide (ICN Biochemicals # 806808) ran at 
130 volts to separate DNA. Agarose gels were placed on UV transilluminator to 
visualize the DNA intercalated by ethidium bromide. DNA bands were excised 
and purified using the Invitrogen DNA extraction kit (K210012). PCR samples 
were prepared for sequencing by cloning them into TOPOII-Blunt (PCR) vector 
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(Invitrogen # K2800-20). Sequencing was performed using M13 forward and M13 
reverse or T7 and T3 primers. All nucleotide sequencing was performed on both 
strands at the Indiana University Biochemistry Biotechnology Facility 
(Indianapolis, IN). 
K. Real-time PCR 
Real-time PCR was performed to quantify the mRNA levels of TgAPE and 
TgAPN in tachyzoites. Total RNA was obtained from RH strain parasites using 
the Qiagen RNeasy kit (Qiagen # 74106) and cDNA was reverse synthesized 
using Omniscript reverse transcriptase (Qiagen # 205111). The cDNA was used 
for the real time PCR reaction. The inverse value CT numbers obtained were 
used to generate data. 
Relative real-time PCR was performed for the conditional knockout 
parasite with and without anhydrous tetracycline. cDNA was once again 
synthesized using Omniscript reverse transcriptase (Qiagen # 205111). Tubulin 
(type, GenBank number, primers) was used as a normalization control in the 
PCR. The cDNA synthesis was set up as follows: 
2 μl 10x Buffer RT  
2 μl dNTP Mix  
2 μl Oligo-dT primer  
1 μl RNase inhibitor  
1 μl Omniscript Reverse Transcriptase  
12 µl RNase-free water 
1 µl template RNA 
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The reaction mixture was incubated at 37°C for 1 hour and then the 
reverse transcriptase was inactivated at 95°C for 5 minutes. All reactions were 
performed in triplicate, using the 7500 real-time PCR system and analyzed using 
SDS software version 1.2.1 (Applied Biosystems). 
L. Protein quantification 
 Protein quantification was performed using the Pierce BCA protein assay 
kit (Thermo scientific # 23225). Protein lysates were made as previously 
described (in section I of materials and methods). 25 µl of each sample was 
loaded into 96-well plates in triplicate. 200 µl working reagent, made from mixing 
reagent A and B 50:1 was added to each sample and incubated at 37°C for 30 
minutes. After allowing the samples to cool to room temperature, the plate was 
read on a Magellan plate reader. The amount of protein in the sample was 
determined based on a standard curve derived from known BSA standards. 
M. Transformation into E. coli 
  Vials containing ligation mixtures are placed on ice. One vial of Oneshot 
Top Ten cells (Invitrogen # C505003) for each reaction is thawed on ice. 5 µl of 
each ligation mixture was added directly to the E. coli and mixed gently by taping. 
Excessive agitation will rapture the fragile competent cells. The bacteria and 
DNA mixture was incubated on ice for 20 minutes before heat-shocking for 30 
seconds in a 42°C water bath. After heat-shock, the bacteria were put on ice. 250 
μl of pre-warmed S.O.C. medium (0.5% yeast extract, 8.6 mM NaCl, 2.5 mM KCl, 
20 mM MgSO4 and 20 mM Glucose) was added to each vial. Transfected 
samples were placed in a shaking incubator at 300rpm and 37°C for 45 minutes. 
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100 µl of transfected E. coli was plated onto an agar plate with the appropriate 
antibiotic. Plates were incubated inverted at 37°C overnight.  
3. High-throughput screen for TgAPN inhibitors 
A. Screening library 
 The ChemDiv library of diverse drug-like compound was used to screen 
for the TgAPN inhibitors. The compounds in this library obey the Lipinski rule of 
five with good ADME (absorption, distribution, metabolism and distribution) 
profiles. The Lipinski rule of five states that drugable compounds should have not 
more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or more 
hydrogen atoms), not more than 10 hydrogen bond acceptors (nitrogen or 
oxygen atoms), a molecular weight under 500 Daltons and a octanol-water 
partition coefficient log P less than 5. The library is formatted and available for 
screening in 384 well plates. The screen was carried out at the Chemical 
Genomics Core Facility in collaboration with Dr. Millie Georgiadis. 
B. Drug screening assay for TgAPN inhibitors 
 The assay used a fluor-quenched pair of oligonucleotides; 5-F-
GCCCCCXGGGGACGTACGATATCCCGCTCC-3’ and its annealed complement 
oligonucleotide 3-Q-CGGGGGCCCCCTGCATGCTGCTATAGGGCGAGG-5’, 
where F is fluorecein, Q is dabcyl, and X is terohydrofuran, an abasic site analog. 
In preliminary studies, varying amounts of recombinant TgAPN and 100 nM of 
substrate (oligonucleotide) are incubated together at room temperature to 
measure fluorescence as a function of time. Cleavage at the abasic site will 
result in the F-GCCCCC product and a time dependant increase in fluorescence 
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following the dissociation of the oligonucleotide duplex. The increased 
fluorescence is due to increased distance between the fluorescein and dabcyl. 
While associated in the oligonucleotide duplex, the fluorecein signal is quenched 
in by the dabcyl due to their close proximity. The high-throughput assay was 
done in a buffer containing: 50 mM Tris-HCl (pH 8.0), 1 mM MgCl2, 50 mM NaCl 
and 2 mM DTT. The Genesis Workstation 150 that has three liquid handling and 
robotic arms for handling the 384 well plates was used to screen the inhibitor 
reactions. The fluorescence readings were monitored continuously through the 
30 minute duration of the experiment using a SpectraMax plus 384 plate reader 
Molecular devices) and Softmax pro software in the kinetic mode at 495 
excitation and 530 emission. 10 µM of compounds were initially screened in the 
reaction and compared to a control sample with no inhibitor to determine the 
level of inhibition. Compounds that had inhibitory activity against recombinant 
TgAPN had reduced fluorescent emission compared to the control sample. 
C. Evaluation of high-throughput screen data 
 For each of the assay plates, 16 values of the control were obtained by 
measuring the fluorescence emitted. The assay reagents were dispensed exactly 
the same way in the sample wells as well as control wells to minimize variability. 
In addition to calculating the standard deviation among the controls and sample, 
a statistical Z factor, commonly used in high-throughput screens was also 
determined. The Z factor is a measure of data scatter and reproducibility in the 
high-throughput screen. Typically the Z factor varies between 0 to 1 with 1 being 
a perfect reaction and a score greater than 0.5 is considered acceptable. 
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Potential hits were also compared to the positive control, lucanthone, which 
inhibits both human and Toxoplasma TgAPE.  
 Once the compounds with inhibitory activity against TgAPN were 
identified in the high-throughput screen, their inhibitory activity is evaluated using 
a standard AP endonuclease assay. The DNA repair assay uses 5-hexachloro-
fluorescein phosphoramidite (HEX)-labeled terahydrofurayl (THF) oligo. The 
oligonucleotide is 26bp long and contains a THF, an abasic site analogue, in the 
middle. Upon DNA repair the AP endonuclease cleaves the oligonucleotide at the 
synthetic AP site (THF) yielding a 13mer fragment. The reaction products can 
then be visualized using a 20% polyacrylamide gel. Different concentrations of 
the inhibitors were added to determine the inhibition of recombinant TgAPN AP 
endonuclease activity. 
D. Evaluating the inhibitory activity of compounds on Toxoplasma 
tachyzoites 
 Compounds were that determined to have inhibitory activity against 
TgAPN were further tested against Toxoplasma tachyzoites. Initial studies were 
done using monolayer disruption assay (discussed under growth assays). 
Concentrations of the inhibitors ranging from 0.05 to 100 µM were added to 
3,000 parasites in 96 well plates containing confluent human fore skin fibroblasts. 
The assay was evaluated for 5 days to determine inhibition of parasite growth. 
Host cell and parasite toxicity were determined as well as any of the compounds 
that crystallized out of solution when diluted in parasite media. 
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 Inhibitors that had no observable toxicity to host cells and inhibited 
parasite growth were further tested using more quantitative growth assays such 
as plaque assays and B1 assays describe previously under growth assays. 24 
well plates of confluent human fore skin fibroblasts were infected with 1,000 
parasites as well as different concentration of inhibitors determined by the data 
from the monolayer disruption assay. Data is collected on day 5 and day 7 for the 
B1 and plaque assay, respectively. In all assays, DMSO, in which the 
compounds were dissolved in, was used as a negative control. Pyrimethamine, a 
potent anti-Toxoplasma drug, was used as a positive control. 
E. Determining host cell toxicity by TgAPN inhibitors 
 Preliminary toxicity of the TgAPN inhibitors on human foreskin fibroblast 
was done by observing the host cell monolayer under a microscope. The toxicity 
was determined by comparing the host cell monolayer infected with Toxoplasma 
tachyzoites alone with a monolayer infected with Toxoplasma and an inhibitor as 
well as a control of an uninfected confluent monolayer. The monolayers were 
fixed with 100% ice cold methanol for five minutes at the end of the experiment 
(5th day).  
4. Miscellaneous 
A. Chemicals 
Methyl methanesulfonate (MMS) was obtained from Sigma (M4016) in 
DMSO at a concentration of 11.8 M (1.3 g/ml) and stored at 4°C. Shield-1 
(CheminPharma, New Haven, # CIP-S1) was dissolved in 100% ethanol at a 
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concentration of 0.5 mM and stored at -20°C. 200 nM Shield-1was added to 
designated parasite cultures to stabilize the indicated fusion protein.  
B. Statistics 
All viability assays and DNA damage assays were performed at least 
three times. The results were reported as the mean standard deviation of the 
three independent experiments. Statistical significance was determined by the 
Student t-test or ANOVA (analysis of variance). 
C. Bioinformatics 
 Bioinformatics was performed using http://www.ToxoDB.org for DNA and 
protein sequence evaluation (ToxoDB accession numbers 35.m00892 and 
80.m00015 for TgAPE and TgAPN, respectively). DNA and protein sequences 
were also analyzed for homologues using BLAST (Basic local alignment search 
tool) programs at http://www.ncbi.nlm.nih.gov. Multiple sequence alignments 
were compiled using Vector NTI 9.0 (Informax) and ClustalW 
(http://www.ch.embnet.org/software/ClustalW). 
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CHAPTER 3: RESULTS 
1. Characterization of Toxoplasma AP endonucleases  
A. Apicomplexan parasites have ExoIII and EndoIV AP endonucleases 
A search of the Toxoplasma genome web site (ToxoDB.org) revealed that 
accession number TGGT1_098640/35.m00892 (chromosome XI) is a homologue 
of human APE1 (hAPE1, ExoIII class) and TGGT1_034710/80.m00015 
(chromosome IX) a homologue of yeast APN1 (EndoIV class). Dr. Sullivan 
subsequently cloned the full-length cDNA and confirmed the sequences for each 
(GenBank accession numbers are HM593513 for TgAPE and HM593514 for 
TgAPN). 5’- and 3’-RACE (rapid amplification of cDNA ends) were performed, 
revealing that TgAPE has a 5’UTR (untranslated region) of 273 nt and 3’UTR of 
320 nt (Figure 9); TgAPN has a 5’UTR of 254 nt and 3’UTR of 424 nt (Figure 10). 
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TTTTCTCTTGTCCGCGTCTCGCGTCGTCTAAGTGCGCCTCTCTGTCTCTGTCTCTTTTCGCCGACTTTGTT
GTCTTCGGACTCGCAGACTCTGTCCCCTCCCCAGGCCTCGCTCTACTTTATCTCCGTTTTTCTGTGCGTTT
TCTTTCGGTTCCATCACCTCTGATCGTGCGTCGTCTCGACCGCGGAACTCTGCTGCTCGCTGTCTTCTGGA
CTTCTCTCCCGACTCTTCTCCGCTCGACCTCGTGTCTCGCCTGCGTACAAGTGCTCATCA 
 
ATGTCTGTTCACAGAGCAGTGAACTCAGCACAGGGAGAAGAGGAAACTGAGGGACCTCATCGAGCAACTAC
AACAGAACTCAACTCATCCGCTGCTTCTCTCTCCTCCTCTCCTTCGTCTGCTCCTTCTTGCCCGGTTTCTA
CTTCAGCTATGCTGCAACGCGCCTCTGATTCGTCCTCTTCCGGCGCTCCGCCTGTCGATTTGAATCCTTCT
CGTGAGACTCGCGAGACGGAGGAGGACGGGGAGGGAGAACTCGAACGGAGAACAGAAGGACCGAAGCGAAA
GGCGCCTTTGAGCATCGTCACCTGGAATGTGAACAGCATCGCAGCGCGAATTCGAGACAGCCGCCAGTGGT
TCTACTTCTCGCGTTTTCTTCAAAAGATCGATCCAGACATTCTTTGTCTCCAAGAAGTCAAACTCGCGGCT
CATGGCCCCCCGGGCGCAAAGAGAGGCGACGGCATGCCGCGAGACCATGGAAGAATAAAGGACTCGGACAA
AGTCAGTAGCGTGGAAGCGCGAGAACTTCGCGAGGCACTCCACACTCTGCTTCCCAACCACAGTCTCCTCA
TCTCGCTGGCAGACTGGAGATATAGCGGACAAATGATGTTCATCAGAAAGGATGTCCAGGTTTGCTCCCTG
CGCTACAACCTGTCCCTCGACGGCTGCCCCGCGCATGAACATGATTTCGAAGGGCGCGTCATTCTGGCGGA
ATTCGAGGCCTTTTGTGTTCTTACCACGTACAGTCCCAACAACGGCGCAACACCGAAGTCGTTCGAGAGAC
GGCGGCTCTGGGATGAACGCATGCTGCAGTTCGTTACTCAATTGAAGAAGCCGCTGGTGTGGGTCGGAGAT
CTGAACTGCGCCCCAGAGGATATCGACCTCTCGGATCCGGATCAGTTTCGCTCGGTCATCCACGAAACCGC
AGACGGCACCATTGATCCGGACAACATTGGACAAGCCGGGTGCACAGATGCCGAGCGGCGGCGTTTTCGGG
CCATTCTCGAGAGGGGGAACCTCGTCGATGCCTTTCGAGAACTGCACCCGCGAACGGAGCCCCCTCCCCTG
GAGAGCGCCGAGTACTCTTGGCGTGGCTTCGGAGGGTCCGGGTCCCGGGGTCTGCTGAGAGGTTTGGGAAT
GCGACTCGACCATATCGTGTTGACGGAGACGCTGATGCCCGCAGTGGAACTCGTGAGAATTTGCGGAGCTG
GAAAGTCAAAGGCGAATTTTTTTGGATCTGATCACTGCCCGGTTCTCGTTCGTTTCAAAGAAAAAGAAATA
TCGGCGTTACCTGCGGTCGTTTGCGAGGCACTGCGCTCCTCTGCTCCTGCGCCAGCTGCGAAGAAGCGGCA
GGACGATTGCCGGTTAGATTCTTTCTTCGCGGTGAAGCGTCGAGCGCAATTGCCAGGTGCAGCGGACCAGA
AAAGGAAGAAGCCGGAGGAAGTTGTCATCTCTGATTCGTCAGACGAGGAGCGGAAAACAAGCCAGAAGATC
GCGCTGCATGCAAGTCTCGAGAAACCGCGAAACGTCCAGGCCTCCAGTTGA 
 
 79 
 
AGAGGAACTGAGCGTCTCGAGGAAACGGAATACTCGGAGTTAGACGACTGGTGTAACTGTCGAAGGTCTGC
AAAACAGGACAGAGACACACAGAGCTGGCGGGGGTGAGAAGAGAGATGATGGTACGGGGGAAGAAGAAAAC
GAATCGAAGAAAGGGAAGCGGCAGAAGCTCTCGGGGTGAGGGAGGCACGTGAGGCCTTCAAACCGGACAGA
AAAAGTGAGAGAGGGTGACGAGGGAATCTGAAGTATTTAAAAGACCGGGCAACGAGAATGTCGAGGTCAAA
CAAAGAAGTTGTCCAAGTCCAATCTGTCTTTGCGTC 
 
Figure 9: Nucleotide sequence of TgAPE. TgAPE gene was cloned and the 
sequence was verified. The 5’ and 3’UTRs (grey) were determined by rapid 
amplification of cDNA ends (RACE). Full length Toxoplasma mRNA was reverse 
transcribed and cDNA was used in RACE reactions to amplify the TgAPE 
untranslated regions. The 5’ UTR is 273 nt and 3’UTR is 320 nt. 
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ACAGTTCTGTCTTTTNNNNNNNNNGTCAATCAGAAAAACGGACTGCCTTTCTGCTGNNNNCCCCCCGAAGT
GTGCATGTACACCTCTTCCTGTCGGCCAGCCAACATCGCTTCGCGTACAAACCTCAATCCGCGGTGGTGTT
ACTTCCAATCAAGCACGATTGTCTGGTGATAGCGTCTTGCTGCCCAGCAAGCAGGGCGACTGAGAGAGAGT
CAACATTGTCTGGTACTTCTGTGTCTGCCAACGGAACAGCG 
 
ATGACGGCTGCAGCGTCCCTAAGAAAAACCAAGGGTGCTGACGCTGCTGCGTCGCAGGGTCGGGCCGGGCa
GCAGCCCCGCGGCGTAAAGCGAGATCAGGCAGATTCCCCAGGTGAACTGCCAGCGACTGAGGAGACTACAA
GTCCGATTTCTAGCGTTTCTCGGGGCGTCTCCGGGTCTGGAAAACCAGTCGTGTCGAAACGGATCAAAACA
GAGCCTGACACCCAGACGACCAGTGCCCATTAGACACAAAAGCGGATGGGACAGCGGACGCGAAGCACTCG
AGTGTCAAGAAAcCGGCGATGAAATCGGAGGCACATGAGGGCAACCATAATGGCACAGAGGGCGAAATGAA
GCAGAAGGTGAATGCGAAGGGGGCGAAAGTTAAGGGTGAGACCGGTGATGAGGCAGACGACACGCAAGAGG
GAGAAGCCAAGAATGGAGGCAAGGCACCGAAGCGATCAGCTGGCAAGAAACAATCAACTGCAGGAAACTTG
CCGACGGAGGTCGACGAAGTTTTTCTCAGGCATCGAGCTGTGGCTGAGAAGAGCCGGAAGTTCCTCGGcGC
TCATATATCAGCTGCTGGAGGTGTTCAGAACGCTCCAGTGAACTGCCTGGCCATCGGAGGACAAGCTTTCG
CTTTCTTTTTGAAGAATCAGCGGCGCTGGGACTCACCGCCGATAAGCGACGAATCAGCAGATGGCTTCAAA
GCCGAGGTGGCGAAGCTGAAGCTCGATGGCCCCGAGCATATCTTGCCTCACGGCTCCTACCTGATCAACTT
AGCGAACCCAGACGCGGCGAAACGCAAGGTGTCCTACAACGCGTTTCTTGACGACCTGCAGAGGTGCGAGC
AGATCGGCGTTCACCGATACGTCTTTCACCCAGGTTCGACGGTTGGCCAGTGCACaAAGGAAGAAAGCATC
AGACATATTGCAGAATGTCTCAATAAGGCAATAGCGGCAACCAAGAGCGTCACGATTCTACTCGAAAACAT
GGCGGGACAGAAGAACGTGCTCTGCAGCGAGTTCGAGGATCTCCGAGATATAATTGCTCTCGTGGACAGGA
AGGACCGCATCGGTGTCTGCCTGGATACGTGCCATCTGTATTCTGCCGGTCATGACATCAAAACGGAAGAA
AAATTTGAAGCGGTGATGAAAAAGTTCGACAGCATCGTTGGCATGAAGTATCTGAAGGCGATGCATATCAA
CGATTCTAAGGCTCCTCTAGGAAGCGGCCTGGACAGACACGAGCACCTCGGAAAGGGCACTCTCGGAATGG
CCCCGTTCAAGTTCATTATGCAGCACCCGACGTGGTTCAAGGACATGCCCCTCGTCCTAGAGACGCCCGAT
GTCGACAACAGTGGTCCAGCCATGTGGCGCAAAGAAACGGAGATGATGTACAAATTCATCGAAGAGTGA 
 
TGTACAAATTCATCGAAGAGTGATGCATGCNCAGGTCATGCCAGGGAAACTGTTTTTCAGGATGGATGCAG
CGGCGACGCTGTACATCTTGGGCTGTCGTGTCGTAGTCGGTCGATAGATGCCGGCTTTAGCTTCCGATTGC
ATGCAGCGAGGCGGTGTTTTTGTCAAGAATGTTTCAGTGGCGCCGTTGAGAAAGCATATTCGATTCCTCAG
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GTGAGAGTGCGGTGCGAATTTCCGGTCTCCGTCGGGTGAAGAAAATACACTTCTTGACTGGCAGATGGTGC
GAAACACATGGGCACACCACTAGTGATGTTTGCGTCAATTTCCGTTTGCACTCGAATGCCGTATTCAAAAC
GCTTCTGATGTTGGCGTAGTGTGAATATTTCAGTCAGAATCAGTGTTGTACGAACTACCTCCGCAACGGCT
TTCATCAAGAAACTGC 
 
Figure 10: Nucleotide sequence of TgAPN. TgAPN gene was cloned and the 
sequence was verified. The 5’ and 3’UTRs (grey) were determined by rapid 
amplification of cDNA ends (RACE). Full length Toxoplasma mRNA was reverse 
transcribed and cDNA was used in RACE reactions to amplify the TgAPN 
untranslated regions. The 5’ UTR is 254 nt and 3’UTR is 424 nt. 
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BLASTp searches with the deduced amino acid sequence for TgAPE 
reveal most significant matches to other apicomplexan APE1 homologues, 
followed by plant species (rice, sorghum, and Arabidopsis), which are ~35% 
identical and ~50% similar. In contrast, TgAPE is less similar to hAPE1. TgAPE 
is comprised of 513 amino acids while hApe1 only has 318 residues; TgAPE 
contains 10 insertions and one deletion as compared to the human sequence, 
which may have important structural consequences. A PSI-BLAST alignment of 
TgAPE to hAPE1 sequences is shown in (Figure 11). Most but not all of the 
residues thought to play an important role in the repair active site are conserved 
in TgAPE, including E96, Y171, N174, D210, N212, D282, and H309 (numbering 
refers to the human sequence). Notably, three residues that are not conserved 
are W280 and F266, which form the walls of the abasic deoxyribose binding site, 
and R177, which fills the position of the missing base in the duplex. These 
residues in TgAPE are M379, S361, and A253, respectively. The fact that some 
of the residues in the active site are not conserved suggests there may be 
important structural differences in the repair active site. Furthermore, amino acid 
sequence comparison of human APE1 against homologues in mouse, E. coli and 
Toxoplasma were done showing percent homology. Mouse (M. musculus) APE1 
showed the most homology with 93% identity followed by E. coli (27%) and 
Toxoplasma (39%), respectively (Figure 11B). 
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Figure 11: TgAPE homology. A) PSI-BLAST sequence alignment of TgAPE and 
hAPE1. B) Diagram showing Exonuclease III family AP endonuclease proteins 
and domains. Diagram showing the homology of Exonuclease III family AP 
endonuclease proteins and domains. All proteins were compared for homology to 
the human (H. sapien) APE1. 
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BLASTp searches with the deduced 472 amino acid sequence of TgAPN 
reveal that the most significant matches are to other apicomplexan APN1 
homologues, followed by fungal species (e.g. Chaetomium globosum, Fusarium 
graminearum, Neurospora crassa, Cryptococcus neoformans) which are ~40-
50% identical and ~60-70% similar. Residues 187 to 463 of TgAPN are 43% 
identical to E. coli EndoIV, which includes 285 residues. Residues involved in 
coordinating the three metal ions in the active site of E. coli EndoIV are 
conserved in TgAPN. These residues include H255, H295, and E331 (numbering 
for TgAPN), which coordinate Zn1, E448, H392, and D365, Zn2, and D415, H417, 
and H368, Zn3. In addition, recognition loop residues, R222 and Y258 are also 
conserved suggesting that mechanistically TgAPN is very similar to E. coli 
EndoIV. In contrast to the APE family enzymes in which the larger TgAPE has a 
number of sequence inserts throughout the enzyme the contribute to its 
significantly larger mass, the difference in size between TgAPN and E. coli 
endonuclease IV results primarily from an N-terminal insertion in TgAPN. The 
amino acid sequence homology of S. cerevisiae APN1 was compared to other 
organisms including Toxoplasma. C. elegans and E. coli showed 41% identity, 
while Toxoplasma had 47% identity to yeast APN1 (Figure 12). 
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Figure 12: TgAPN homology. A) PSI-BLAST sequence alignment of TgAPN and 
yeast Saccharomyces cerevisiae APN1 (Endo IV). B) Diagram showing the 
homology of Exonuclease III family AP endonuclease proteins and domains. All 
proteins were compared for homology to the S. cerevisiae APN1.  
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Previous studies and comparative genomics reveal additional insight into 
the AP endonucleases in Apicomplexa. Biochemical evidence suggested that 
Plasmodium falciparum (malaria) contains both Mg2+-dependent (APE1) and 
Mg2+-independent (APN1) AP endonuclease activities (Haltiwanger et al., 
2000a); we have verified that the Plasmodium genome sequence harbors genes 
for both APE1 (chr3.glimmerm_170) and APN1 (chr13.genefinder_182r) 
homologues. Survey of the Cryptosporidium genome also reveals both APE1 
(CpIOWA_EAK87392) and APN1 (CpIOWA_EAK88592) homologues. 
Phylogenetic analysis shows that apicomplexan APN1 homologues form a clade 
with yeast APN1, while apicomplexan APE1 homologues are more closely 
related to those found in plants rather than mammals (Figure 13).  
 
  
 89 
 
 
Figure 13: Phylogenetic analysis of APE1 and APN1 homologues. Dendogram 
was composed using AlignX module of Vector NTI Advance 9.0 software 
(Informax). Gray box indicates plant APE1 homologues; light green box indicates 
apicomplexan APN1 homologues. At=Arabidopsis thaliana; B=Brachydanio rerio 
(zebrafish); Cp=Cryptosporidium parvum; Dd=Dictyostelium discoideum (slime 
mold); Gl=Giardia lamblia; Hs=Homo sapiens; Lm=Listeria monocytogenes; 
Pf=Plasmodium falciparum (malaria); Os=Oryza sativa (rice); Rn=Rattus 
norvegicus; Sc=Saccharomyces cerevisiae; Sv=Sorghum vulgare; 
Tg=Toxoplasma gondii; Xt=Xenopus laevis.  
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B. Recombinant TgAPE and TgAPN 
 TgAPE and TgAPN were cloned and expressed in E. coli. The 
recombinant proteins were purified and analyzed on an SDS-PAGE gel and 
determined to be the sizes predicted on http://www.toxodb.com. TgAPE 
recombinant protein was observed as a doublet between 54- 57 kDa, while 
TgAPN was observed at 51 kDa (Figure 14). 
 
  
Figure 14: Purified recombinant TgAPE and TgAPN SDS-PAGE analysis. TgAPE 
(lane 1) and TgAPN (lane 2) expressed in Rosetta E. coli and purified using 
nickel affinity chromatography. (Millie M. Georgiadis, unpublished data). 
  
kDa 
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C. TgAPE and TgAPN AP DNA repair activities 
We expressed recombinant TgAPE and TgAPN in E. coli and purified the 
proteins for enzymatic analysis. The DNA repair assay utilizes a 5’-hexachloro-
fluorescein phosphoramidite (HEX)-labeled terahydrofuranyl (THF) oligo (the 26 
bp oligonucleotide substrate contains a single THF residue in the middle, yielding 
a HEX-labeled 13mer fragment upon repair). THF is a stable synthetic abasic 
site. The reaction products are visualized after resolving on 20% polyacrylamide 
gels. As predicted from their structural similarities to hAPE1 and yeast APN1, the 
TgAPE enzyme should require Mg+2 while TgAPN should be Mg+2-independent. 
As shown in Figure 15, TgAPE is capable of cleaving the THF oligo as evidenced 
by the accumulation of the lower 13 bp product with increasing concentrations of 
enzyme and is only active in the Mg+2-containing buffer. TgAPN also displays AP 
endonuclease activity and is active in the presence or absence of Mg+2 (Figure 
15). 
We measured total AP endonuclease activity levels in wild-type 
Toxoplasma lysate using the AP endonuclease gel assay (Figure 15). The 
percent activity was expressed as a percent of the value of the cleaved oligo to 
the total value of the cleaved and uncleaved oligo. TgAPN (Mg2+-independent) 
activity levels were measured by using Mg2+-free buffer containing EDTA. In both 
cases, a dose-dependent increase of activity was seen with increasing amounts 
of parasite lysate present in the reaction. The results demonstrate that TgAPN 
contributes substantially to the total amount of AP endonuclease activity detected 
in parasite lysate.  
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Figure 15: AP endonuclease assay. A) Increasing amounts of rTgAPE were 
incubated in buffer A (50mM HEPES, 50mM KCl, 10mM MgCl2,1 µg/ml BSA, 
0.05%TritonX-100, pH 7.5). B) Increasing amounts of rTgAPN were incubated in 
buffer B (50mM HEPES, 50mM KCl, 20mM EDTA,1 µg/ml BSA, 0.05%TritonX-
100, pH 7.5). All reactions contained 1mM DTT and 0.05 pmol HEX-TEF 
oligonucleotide in a total of 10 µl and were incubated at 37ºC for 15 minutes. AP 
endonuclease assays were performed in the laboratory of Dr. Mark Kelley. 
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Figure 16: AP endonuclease activities in Toxoplasma lysate. A) Total AP 
endonuclease activity in wild-type Toxoplasma lysate, performed in presence of 
1.0 mM MgCl2. Lane 1, 10 nM recombinant human APE1 (PC, positive control); 
lane 2, DNA alone (NC, negative control); lanes 3-8, increasing amounts of 
Toxoplasma lysate (100, 250, 500, 1000, 1500 and 3000 ng, respectively). The 
columns on the graphs below each gel correspond to the percent activity of the 
sample directly above and are representative of the average percent activity of 
two independent assays. B) APN activity levels in parasite lysate, as determined 
by degree of cleaved oligonucleotide. AP endonuclease assays were performed 
in the presence of 10 mM EDTA to chelate Mg2+. Lane 1, 10 nM recombinant 
TgAPN (PC, positive control); lane 2, DNA alone (NC, negative control); lanes 3-
8, increasing amounts of Toxoplasma lysate (100, 250, 500, 1000, 1500 and 
3000 ng, respectively). 
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Further steady state enzymatic characterizations of TgAPN and TgAPE 
were performed in the lab of Dr. Millie Georgiadis using a fluorescent-based 
solution assay as described in the Materials and Methods (Section III). The THF-
containing oligonucleotide substrate concentration was varied from 0 to 75 nM, 
and Michaelis-Menton Km values of 26.2 and 21.1 nM and Vmax values of 1458 
and 110,070 RFU/ g/s, respectively for TgAPN vs. TgAPE, were calculated 
(Figure 17), where RFU is a relative fluorescent unit. Thus, while the relative 
binding affinities of each enzyme for the substrate are similar, the turnover rate is 
approximately 75 times faster for TgAPE. 
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Figure 17: TgAPE and TgAPN AP endonuclease assays. A fluorescent-based 
solution assay was used to characterize the steady state kinetic properties of 
TgAPE (A) and TgAPN (B). Using optimized concentrations of TgAPE (0.05 nM) 
and TgAPN (4 nM) and substrate concentrations from 0 to 75 nM, Km values of 
21.1 and 26.2 nM, respectively, were determined. Vmax values for the two 
enzymes differ by a factor of 75, with TgAPE exhibiting the more rapid rate of 
endonuclease activity. 
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D. Size of Toxoplasma AP endonucleases 
Polyclonal antisera were generated in rabbits using the recombinant 
TgAPE and TgAPN purified from bacteria as antigen. Polyhistidine tags were 
removed by proteolytic cleavage prior to immunization. Antibodies were affinity-
purified and used to probe Western blots containing lysates from Toxoplasma 
tachyzoites or the recombinant protein as control (Figure 18). Recombinant 
TgAPE migrates at the expected MW of 57 kD, but also appears at 52 kD, 
possibly a breakdown or proteolytic product. Native TgAPE expressed in 
Toxoplasma also migrates as two proteins as seen when produced in E. coli, 
making it likely that this is protein processing rather than an alternatively spliced 
product. Native TgAPN migrates slightly higher than the expected 51 kD in 
Toxoplasma lysate, possibly due to a post-translational modification(s). 
 
 
Figure 18: Size of TgAPE and TgAPN. Western analysis with affinity-purified anti-
TgAPE or anti-TgAPN, each used at a 1:10,000 dilution. The designated amount 
of Toxoplasma protein lysate is shown. Recombinant (r) protein expressed and 
purified from E. coli was run as control.  
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E. Localization of Toxoplasma AP endonucleases 
TgAPE and TgAPN antibodies were used in immunofluorescence assays 
(IFA) to localize the native protein in Toxoplasma tachyzoites growing inside their 
host cells. Native TgAPE is present in the parasite nucleus and cytoplasm while 
native TgAPN is nuclear (Figure 19). Arrowheads point to potential TgAPE 
present in the apicoplast, a specialized organelle housing a 35 kb 
extrachromosomal element. We did not detect TgAPN in organelles housing 
extrachromosomal DNA, such as the apicoplast or mitochondria. 
 
Figure 19: Localization of Toxoplasma AP endonucleases. IFA of intracellular 
parasites probed with 1:1,000 dilution of anti-TgAPE (top panels, green) or 
1:10,000 dilution anti-TgAPN (lower panels, green). 4’,6-diamidino-2-
phenylindole (DAPI) was used as a co-stain to highlight the nuclear compartment 
(blue). hN=host cell nucleus. Arrowheads point to parasite apicoplast organelle. 
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F. TgAPN is more abundant than TgAPE in tachyzoites 
In other species possessing more than one AP endonuclease, one tends 
to be the predominant enzyme that is critical for BER [59]. We therefore sought 
to establish which AP endonuclease was predominant in Toxoplasma 
tachyzoites. An analysis of the expressed sequence tags (ESTs) data at the 
ToxoDB Release 6.0 (http://www.toxodb.org) shows that only 6 ESTs represent 
TgAPE whereas >65 ESTs were identified for TgAPN, indicating that TgAPE 
message levels are very low compared to those encoding TgAPN (Figure 20). 
Real time PCR analysis also shows more TgAPN message than TgAPE.  
 
Figure 20: Levels of TgAPE and TgAPN mRNA. A) Real time PCR data showing 
levels of TgAPE and TgAPN mRNA. The values represent the inverse Ct 
numbers of the respective message. B) Partial screen shot of the EST data for 
TgAPE and TgAPN from http://www.toxodb.com. 
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Analysis at the protein level also supports that TgAPN is the more 
prevalent AP endonuclease. Proteomics data at the ToxoDB mirrors what we 
observed for ESTs in that a large number of peptides in various independent 
datasets (e.g. generated by Wastling, Hu, or Einstein labs) suggest TgAPN is 
present in abundance at the protein level; in contrast, only 5 peptides have been 
reported matching to TgAPE (Figure 21A). Immunoblots of tachyzoite lysate with 
antibodies to TgAPE and TgAPN further support that TgAPN is the more 
abundant protein (Figure 21B). Considered together, these multiple lines of 
evidence indicate that TgAPN is more abundant than TgAPE at both the RNA 
and protein levels in tachyzoites. 
 
Figure 21: Levels of TgAPE and TgAPN protein. A) A partial screenshot of 
proteomics data available from http://www.toxodb.com for TgAPE and TgAPN. B) 
Western analysis with affinity-purified anti-TgAPE or anti-TgAPN, each used at a 
1:10,000 dilution. The designated amount of Toxoplasma protein lysate is shown. 
Recombinant (r) protein expressed and purified from E. coli was run as control.  
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G. Over-expression of TgAPE and TgAPN 
To determine if over-expression of TgAPE or TgAPN confers protection 
against DNA damage, we expressed recombinant FLAG-tagged versions of 
TgAPE or TgAPN (tagged at N-terminus) in RH strain tachyzoites (FLAGAPE or 
FLAGAPN). Expression of each ectopic copy was driven by the same strong 
tubulin promoter as previously described [90]. Western blot analysis showed that 
both selected transgenic clones were expressing more TgAPE or TgAPN protein 
than wild-type parasites. Immunoblots also show that there is more FLAGAPE 
compared to FLAGAPN in the over-expressing lines (Figure 22). Also note that only 
the full-length TgAPE appeared on the immunoblot probed with anti-FLAG, 
suggesting that the shorter form of TgAPE is missing a portion of its N-terminal 
region. 
 
 
 
Figure 22: Expression levels of ectopic FLAG-tagged AP endonucleases. Ten µg 
of parasite lysate was loaded for immunoblotting with anti-TgAPE (1:10,000), 
anti-TgAPN (1:10,000), or anti-FLAG (1:5,000). Anti-tubulin (1:5,000) was used 
to check protein loading.  
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We also performed IFAs to determine the subcellular localization of each 
tagged Toxoplasma AP endonuclease (Figure 23). When anti-APE or anti-APN 
antibodies are used in IFAs of the parasites over-expressing FLAG-tagged 
TgAPE or TgAPN, the staining pattern is identical to that seen for wild-type 
parasites. Moreover, anti-FLAG IFAs of parasites expressing FLAGAPN confirm 
nuclear localization of this protein. In contrast to IFAs with anti-APE, anti-FLAG 
IFAs of parasites expressing FLAGAPE show almost exclusive localization to the 
nucleus. This suggests that the cytosolic staining for native TgAPE is due to the 
fact that anti-APE recognizes both full-length and truncated forms. In other 
words, full-length TgAPE is nuclear, but the shorter TgAPE (which anti-FLAG 
would not recognize) is cytoplasmic (Figure 23 B).  
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B. 
 
 
Figure 23: Localization of FLAG-tagged AP endonucleases. A) IFA was 
performed on intracellular parasites expressing FLAGAPE (top panels) or FLAGAPN 
(bottom panels). Parasites were probed with anti-FLAG (1:5,000, red) and either 
anti-TgAPE (1:1,000, green) or anti-TgAPN (1:10,000, green). DAPI was used as 
a co-stain to highlight the parasite nucleus (blue). B) Diagram depicting TgAPE 
cleavage products and possible localization in Toxoplasma tachyzoites. 
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H. Parasites over-expressing TgAPN, but not TgAPE, are protected from 
DNA damage mediated by MMS 
We examined if our transgenic parasites over-expressing recombinant 
forms of each AP endonuclease under control of the same heterologous 
promoter (tubulin) exhibited cytoprotection against the alkylating agent methyl 
methanesulfonate (MMS), a well-established DNA-damaging agent used to study 
BER. Using three independent growth assays, we found that Toxoplasma 
tachyzoites exposed to MMS have increased viability only when TgAPN is stably 
over-expressed; no protection is conferred when TgAPE is over-expressed 
(Figure 24). Figure 24A is a PCR-based assay for the parasite-specific B1 
sequence that monitors growth over 5 days following exposure to an insult of 400 
µM MMS for 2 hrs. A plaque assay performed at day 7 following 400 or 800 µM 
MMS produced similar results (Figure 24B). Finally, a Toxoplasma doubling 
assay performed on parasites over a time course following exposure to 800 µM 
MMS verified that those over-expressing TgAPN were remarkably refractory to 
this insult (Figure 24C). It should be noted that the growth rates of each over-
expressing line are virtually identical to each other as well as wild-type under 
vehicle-treated conditions.  
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Figure 24: DNA damage recovery assays. Extracellular parasites (wild-type, WT), 
FLAGAPE and FLAGAPN) were subjected to DNA damage induced by MMS or 
vehicle control (DMSO) for 2 hr and then allowed to infect fresh HFF monolayers 
under normal culture conditions. A) Parasite growth was monitored by PCR-
based B1 assay following exposure to 400 µM MMS. B) Parasite growth was 
measured using a plaque assay in either 400 or 800 µM MMS. C) Parasite 
doubling assays were performed following exposure to 800 µM MMS. Error bars 
represent standard deviation. Significance determined by t-test (P<0.05). 
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I. TgAPN conditional knockout 
To definitively demonstrate that TgAPN is vital for Toxoplasma DNA 
repair, we designed experiments to ablate or diminish TgAPN levels in the 
parasite. We attempted to knockout the TgAPN locus in type I RH strain 
parasites using conventional homologous recombination. No viable clones were 
obtained, possibly because the TgAPN gene is essential. To test this idea, we 
created a conditional knockout for TgAPN in the TATi parasite background, 
which expresses a transactivator protein that can be regulated by 
anhydrotetracycline (ATc) [78]. Ectopic HA-APNFLAG driven by the ATc-responsive 
SAG1 promoter was stably expressed in TATi parasites (Figure 25 and 26).  
 
Figure 25: Diagram representing the tet-regulatable TgAPN ectopic gene. The 
tet-transactivator binds to the tet-regulatable promoter and the TgAPN is 
expressed. When anhydrous tetracycline (ATc) is added, it binds the tet-
transactivator, preventing association with the tet-regulated promoter and 
repressing expression of TgAPN. CAT=chloramphenical acetyltransferase. HA 
and FLAG are tags used to detect ectopic TgAPN. 
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Figure 26: Expression of ectopic TgAPN is regulated by ATc. A) IFAs showing 
regulatable TgAPN in the presence or absence of 1 µg/ml ATc. B and C) 
Western blots of parasite lysates in the presence or absence of ATc. TgAPN 
antibody=1:10,000 (green), FLAG antibody=1:5,000 (red), tubulin antibody= 
1:5,000 DAPI was used as a nuclear co-stain (blue). 
  
 107 
 
Next, the entire endogenous locus encoding TgAPN was eliminated 
through homologous recombination in the tet-regulatable clone shown in Figure 
27. 3.5 kb of DNA was amplified from the flanking regions of the TgAPN genomic 
locus. These pieces were ligated to a vector conferring pyrimethamine resistance 
and transfected into the parasites. Over 130 pyrimethamine-resistant clones 
were screened and a single knockout was obtained and verified by PCR as well 
as Western blotting (Figure 27). Two sets of intron spanning primers (ISP1 and 
ISP2, which amplify 400 bp and 600 bp fragments, respectively) were used to 
screen the clones for the conditional knockout by PCR (Figure 27A and B). The 
knockout could be detected by the absence of an amplicon when using the intron 
spanning primers. TgAPN 5’ UTR primers, which amplify a 400 bp fragment, 
were used as a positive control to ensure the presence of quality DNA template. 
Western blot analysis using anti-TgAPN confirmed the knockout, showing loss of 
the native protein band in the knockout parasite (Figure 27C). The wild-type 
TgAPN protein was detected as a single band at the expected size. The TgAPN+ 
ectopic TgAPN clone exhibits two bands with the higher MW band being the 
ectopic copy and the lower MW band being the native protein. In the conditional 
knockout, only the ectopic regulatable TgAPN is detected. 
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Figure 27: Conditional knockout of TgAPN. A) Diagram of knockout vector (red) 
and homologous recombination with the TgAPN genomic locus (blue). Intron 
spanning primers (ISP). B) PCR screening of TgAPN conditional KO using intron 
spanning primers. The 5’UTR primer set was used as a positive control to 
confirm the quality of the DNA. C) Western blot confirmation of TgAPE 
conditional KO. 10 µg of protein was used for each sample. Antibody 
concentration used was: TgAPN antibody 1:10,000. Tubulin antibody 1:5,000. 
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Unfortunately, addition of 1.0 µg/ml ATc for 48 hrs did not significantly 
reduce the amount of ectopic TgAPN in the conditional knockout clone below the 
level of wild-type parasites, as determined by relative real-time RT-PCR as well 
as Western blot. Both real-time PCR and Western blotting show a significant 
reduction of ectopic TgAPN, but not less than wild-type parasites (Figure 28). 
The problem appears to be that the ectopic TgAPN is expressed at dramatically 
higher levels than endogenous TgAPN, making it difficult to down-regulate 
protein to levels below normal. Similar problems using the tet-based SAG 
promoters have been reported [91]. 
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Figure 28: Down-regulation of ectopic TgAPN in the conditional knockout. A) 
Relative real-time RT-PCR of conditional KO in the presence or absence of 1 
µg/ml ATc. Tubulin was used to normalize the samples. RQ values represent 
relative quantification to tubulin. Error bars represent standard deviation. The 
asterisk denotes statistical significance determined by t-test. P< 0.05.B) Western 
blot of WT and conditional KO in the presence or absence of 1 µg/ml ATc. 10 µg 
of protein lysate was used for each sample. TgAPN antibody was used at 
1:10,000. Tubulin antibody was used at 1:5,000.  
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Higher levels of anhydrous tetracycline did not yield greater down-
regulation of TgAPN compared to 1.0 µg/ml. Toxicity studies showed that 
exceeding 1.4 µg/ml of ATc began to exert toxicity on the TATi parental parasite 
strain (Figure 29). 
 
Figure 29: Anhydrous tetracycline toxicity. 1,000 parasites were allowed to infect 
host cell monolayers and exposed to different concentrations of ATc continuously 
for 7 days. ATc was added to cultures at the beginning of the experiment during 
parasite infection. After one week, infected monolayers were fixed in methanol 
and parasite plaques counted. All samples were performed in triplicate and the 
average was used as the final measurement. Error bars represent standard 
deviation. 
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To test if reduced TgAPN increases susceptibility to MMS, intracellular 
parasites were treated with 1 µg/ml ATc for 24 hours and treated for two hours 
extracellularly with MMS before being placed into culture for a plaque assay. A 
modest slow growth phenotype accompanied the conditional knockout cultured 
in1.0 µg/ml ATc following pre-treatment with 400 µM MMS, consistent with the 
idea that TgAPN is important for Toxoplasma DNA repair (Figure 30). 
 
 
Figure 30: MMS DNA damage recovery assay. 1,000 parasites were treated with 
400 µM MMS for 2 hours prior to infection of host cell monolayers. 1.0 µg/ml of 
ATc was added to the parasites at the time of infection to deplete TgAPN. 
Infected cells were fixed and parasite plaques counted on the seventh day post-
infection. The error bars represent standard deviation. 
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J. Impaired response to DNA damage in TgAPN knockdown parasites 
 As an alternative approach to evaluate if reduced levels of TgAPN would 
result in greater sensitivity to MMS, we used a ligand controlled destabilization 
domain. We engineered a ―knock in‖ vector designed to place a fusion tag onto 
the C-terminal end of TgAPN consisting of two HA epitopes and a destabilization 
domain (2xHA-DD), which allows for regulated expression of the fusion protein 
through addition of the stabilizing ligand Shield-1 [92]. RH strain parasites lacking 
Ku80 (Ku80-KO), which display a significantly higher degree of homologous 
recombination [93], were used to create Toxoplasma parasites expressing 
endogenous TgAPN fused to the 2xHA-DD tag (called TgAPN-2xHA-DD, Figure 
31). We were able to obtain several clones tagged in this fashion that behaved 
similarly. The ability to regulate levels of TgAPN-2xHA-DD protein with Shield-1 
was verified using IFA and immunoblotting (Figure 32A and B).  
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Figure 31: Diagram of Shield-1 regulation of TgAPN. The TgAPN gene is tagged 
at the 3’end to encode a protein with 2xHA and the destabilization domain (DD) 
fused to the C-terminus. The TgAPN-2xHA-DD fusion protein is expressed and 
sent to the proteosome for degradation in the absence of Shield-1. In the 
presence of Shield-1, the destabilizing effect is inhibited, allowing the protein to 
accumulate. 
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Figure 32: Knockdown of TgAPN protein using ligand-controlled destabilization 
domain. A parasite clone was generated to express endogenous TgAPN fused to 
a tag containing two HA epitopes and a destabilization domain (2xHA-DD). A) 
TgAPN-2xHA-DD is rapidly degraded unless stabilized through the inclusion of 
100 nM Shield-1 in the media. IFA of TgAPN-2xHA-DD parasites grown with (+) 
or without (-) Shield, probed with anti-TgAPN (1:10,000, green) or anti-HA 
(1:2,000, red). DAPI was used as a nuclear co-stain (blue). hN=host cell nucleus. 
B) Western blot analysis of TgAPN-2xHA-DD parasites grown with (+) or without 
(-) Shield, probed with anti-HA (1:3,000, left) or anti-TgAPN (1:10,000, right). 10 
µg of parasite lysate was used for the immunoblots. Tubulin was monitored as a 
loading control (1:5,000). 
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(+) Shield
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TgAPN-2xHA-DD parasites cultured under normal conditions without 
Shield (TgAPN knockdown) are viable, as reported for other species [94]. We 
then analyzed the ability of purified, extracellular TgAPN knockdown parasites to 
recover from a direct 2 hr exposure to 25 µM MMS. Relative to the Ku80-KO 
parental line, the TgAPN knockdown parasites were modestly impaired in 
recovering from the 25 µM MMS pre-treatment for 2 hours (Figure 33A). As 
shown, the parental Ku80-KO parasites show ~40% reduction in growth in the 
presence of 100 µM MMS continuously for 7 days. In contrast, TgAPN 
knockdown parasites show ~80% reduction in growth in the presence of 100 µM 
MMS (Figure 33B). Together these data further support that TgAPN plays a role 
in the DNA damage response in Toxoplasma. 
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Figure 33: TgAPN knockdown parasites impaired response to DNA damage. A) 
Parental (Ku80-KO) and TgAPN-2xHA-DD parasites cultured without Shield 
(TgAPN knockdown, KD) were purified and subjected to 25 µM MMS for 2 hrs 
prior to being placed back in culture to infect fresh host cells. Growth was 
monitored on day 5 using the PCR-based B1 assay. B) Parental (Ku80-KO) and 
TgAPN-2xHA-DD parasites cultured without Shield were allowed to infect HFF 
monolayers incubated in the presence of 100 µM MMS (white bars) or vehicle 
control (black bars). Growth was monitored on day 7 using the B1 assay. Error 
bars represent standard deviation. 
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K. Levels of TgAPE in TgAPN knockdown parasites 
 The levels of TgAPE in the TgAPN conditional knockout (see Figure 22) 
and the TgAPN knockdown parasites were analyzed to check if an upregulation 
of TgAPE occurred that might compensate for the loss of TgAPN. Protein levels 
of TgAPE were determined in the conditional knockout cultured with or without 
anhydrous tetracycline. Immunoblots show that levels of TgAPE protein remain 
unchanged in parasites with diminished levels of TgAPN (Figure 34A). 
Immunoblots were also performed for the TgAPN-2x-DD knockdown parasites 
under the control of the destabilization domain. The data suggest that TgAPE is 
not upregulated when TgAPN is depleted. (Figure 34 B). However, these studies 
do not rule out the possibility that there may be overlapping roles for TgAPE and 
TgAPN. 
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Figure 34: Level of TgAPE protein in parasites with down-regulated TgAPN. A) 
TgAPE levels in tet-based TgAPN conditional KO. 1 µg/ml ATc was used to 
reduce the levels of TgAPN. Intracellular parasites were treated with ATc for 48 
hours before the Western blots were performed. B) TgAPE levels in TgAPN-
2xHA-DD parasites with diminished levels of TgAPN. 100 nM Shield-1 was 
added to cultures for 48 hours prior to harvesting the parasites for Western 
blotting. TgAPN antibody used at 1:10,000, TgAPN antibody used at 1:10,000 
and tubulin antibody used at 1:5,000. 
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2. Pharmacological inhibition of TgAPN 
 This section describes our pharmacological approach to inhibit the 
function of TgAPN using small molecule compounds identified in a high-
throughput screen. The screen against recombinant TgAPN activity identified 
nine compounds with potent inhibitory activity. Compound 4491-0277 was found 
to be the most potent inhibitor of Toxoplasma growth in vitro. Moreover, 4491-
0277 is not overtly toxic to human host cells. 
A. Characterization of TgAPN inhibitors 
Prior to the start of this project, there were no inhibitors of APN from any 
species. In collaboration with Dr. Millie Georgiadis, a high-throughput screen for 
a specific inhibitor of TgAPN was carried out using the ChemDiv library with over 
60,000 compounds. The library is comprised of ―drugable‖ compounds that follow 
the Lipinski’s rule of five: not more than 5 hydrogen bond donors (nitrogen or 
oxygen atoms with one or more hydrogen atoms), not more than 10 hydrogen 
bond acceptors (nitrogen or oxygen atoms), a molecular weight under 500 
Daltons and a octanol-water partition coefficient log P less than 5. The 
compounds also possess good ADME (absorption, distribution, metabolism and 
excretion). 
The drug screen used a fluor-quenched pair of oligonucleotide with a 
synthetic abasic site. One strand of the oligonucleotide had a fluorecein molecule 
and the other dabcyl, a quencher. The fluorescence of the fluorecein is quenched 
by the close proximity to the dabcyl while associated in the oligonucleotide 
duplex. When cleavage at the abasic site mimic (terohydrofuran) occurs, it 
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results in disassociation of the oligonucleotides, thereby increasing fluorescence 
as the fluorecein and the dabcyl move further away from each other. 
The initial screen yielded 9 promising compounds that had strong 
inhibitory activity against recombinant TgAPN. The nine compounds were tested 
against Toxoplasma tachyzoites using a standard monolayer disruption assay. 
Pyrimethamine, a known inhibitor of Toxoplasma proliferation, was used as a 
positive control for the assays while DMSO was the vehicle for the compounds. A 
know inhibitor of human APE1 was also tested to analyze its specificity and cross 
reactivity with Toxoplasma AP endonucleases Table IV shows the results of the 
initial characterization of the compounds. 
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Table IV: Effect of TgAPN inhibitors on Toxoplasma viability. 
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All compounds were initially dissolved in DMSO and serially diluted in 
DMEM media to the test concentrations. 3,000 parasites were added to each well 
in 96 well plates with confluent host cells in presence of compound or vehicle 
control. The parasites were allowed to grow for 5 days before monolayer 
disruption was scored as follows: 3=maximum parasite death, 2=moderate 
parasite death, 1=minor parasite death, 0=no effect on parasites, Toxic=toxic to 
host cells. The effect of the inhibitors on the parasite viability was determined 
subjectively under a microscope. 
B. Further characterization of compounds 
 Based on the results of the monolayer disruption assays, three 
compounds most effective in inhibiting parasite proliferation included: 4491-0277, 
C699-0451 and 4491-1565. These three compounds were further characterized 
using the more quantitative PCR-based B1 assay (Figure 35). Concentrations 
tested were based on the results of the initial monolayer disruption assay (Table 
IV). All compounds resulted in a reduction of parasite viability in a dose-
dependent manner. Compound 4491-0277 had the highest inhibitory activity on 
parasite proliferation with an IC50 of 0.4 µM based on the B1 assays done.  
 The structure of the TgAPN inhibitors: 4491-0277, C699-0451 and 4491-
1565 are structurally similar to each other. 4491-0277 and 4491-1565 retain the 
most structural similarity, while C699-0451 retains the related ring structure 
(Figure 36). 
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Figure 35: B1 assay of TgAPN inhibitors. 1,000 parasites were added to each 
well of a 24 well plate with confluent host cells. Compound dilutions were made 
in DMSO. Serial dilutions of different concentrations of inhibitors were made in 
DMEM media and added to the host cells and parasites. The cultures were 
incubated for 5 days and then DNA was isolated from the parasites using 
DNeasy kit and used for the B1 assay. 1.0 µM of pyrimethamine was used as a 
positive control and DMSO as a negative control. Error bars represent standard 
deviation. 
 
Figure 36: TgAPN inhibitor structures. TgAPN inhibitor structures obtained from 
the ChemDiv library. 
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We have also examined the impact of compound 4491-0277 on 
Toxoplasma using a plaque assay, which allows us to observe if there is overt 
toxicity to the HFF host cells. The plaque assay was done by allowing 1,000 
parasites to infect the HFF monolayer in the presence of 1.0 µM of compound 
4491-0277. The compound 4491-0277 was added to the culture at the time of 
infection and left on through the duration of the experiment (5 days). Infected 
host cell monolayers were analyzed under a microscope to determine parasite 
and host cell viability. An uninfected confluent monolayer was included as a 
control. Consistent with data from the B1 assay, Toxoplasma treated with 1.0 µM 
of the compound 4491-0277 ceased to replicate (Figure 37, right panel). It is also 
important to note that the infected host cell monolayer treated with 4491-0277 
showed no overt damage (Figure 37, right panel). These findings suggest that 
TgAPN inhibitor 4491-0277 stops tachyzoite proliferation in vitro at 
concentrations that do not appear to cause overt toxicity to the human host cells. 
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Figure 37: Compound 4491-0277 toxicity to host cells. Photomicrographs of host 
cell monolayers response to parasite infection and compound 4491-0277. 1,000 
parasites were infected onto host cell monolayers and cultured for 5 days. 1.0 µM 
of 4491-0277 was added to the culture at the start of infection. At the end of the 
experiment, infected monolayers were fixed using methanol and analyzed under 
a microscope (X40 magnification).  
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CHAPTER 4: DISCUSSION 
1. Aim 1: Determine the role of TgAPN in Toxoplasma in DNA damage 
A. Summary of Aim 1 results 
 We have identified two AP endonucleases in Toxoplasma: TgAPE and 
TgAPN. TgAPN is a homologue of yeast and bacterial endonuclease IV 
enzymes. TgAPE, a homologue of Exo III enzymes, is expressed as two forms, 
one of which is a truncated version. TgAPE localizes to the parasite nucleus as 
well as the cytoplasm. TgAPN localizes only to the nucleus of the parasites. 
Native TgAPN is larger than rTgAPN, suggesting a post-translational modification 
may occur within parasites. There is a great disparity in the abundance of the two 
Toxoplasma AP endonucleases. TgAPN is more abundant than TgAPE at both 
mRNA and protein levels. Both enzymes show the expected enzymatic activity, 
although recombinant TgAPE displays higher substrate turnover than TgAPN in 
vitro. This higher turnover of TgAPE may indicate that the enzyme can process 
more abasic sites than TgAPN, but further study is required to determine if this 
occurs in vivo. TgAPN over-expression confers protection against MMS. A 
complete knockout of TgAPN did not yield any viable parasites necessitating a 
conditional knockout approach. Depletion of TgAPN in Toxoplasma tachyzoites 
results in increased susceptibility to MMS. 
B. Impact of Toxoplasma infection 
A number of protozoal species in phylum Apicomplexa have a tremendous 
impact on human health and livestock. In addition to Toxoplasma, other 
important pathogens in this phylum include Plasmodium, Cryptosporidium, and 
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Eimeria. In humans, the relationship between immunosuppression and 
occurrence of severe toxoplasmosis is well recognized. In human 
immunodeficiency virus (HIV)-infected patients, the incidence of toxoplasmic 
encephalitis is a leading cause of death [15]. Toxoplasma infection is also an 
important health risk in organ transplants [20]. Congenital toxoplasmosis also 
occurs and might lead to abortion or birth defects in newborns [8]. Plasmodium is 
the causative agent of malaria and kills up to 2.7 million persons per year, over 
75% of them children [95]. Cryptosporidium causes acute diarrheal illness that 
can be extremely serious in the young and immunocompromised. Eimeria is a 
coccidian parasite of poultry, causing losses in excess of $3 billion annually to 
US agribusiness [96]. A combination of too little research and rapid spread of 
resistance to frontline drugs is grossly hindering our control of these infectious 
diseases. 
C. Toxoplasma susceptibility to DNA damage 
 Like other apicomplexans, Toxoplasma is an intracellular parasite likely to 
be exposed to an oxidative burst generated by the host immune response in 
addition to reactive oxygen species (ROS) generated through its own 
metabolism. ROS including hydrogen peroxide, the superoxide radical and the 
hydroxyl radical, are produced as byproducts of oxygen metabolism in all cells. In 
addition, immune effector cells including neutrophils, eosinophils, and 
macrophages release superoxide anion radicals as part of the oxidative burst 
during a microbial infection [47]. A common feature among the different ROS 
types is their capacity to cause oxidative damage to proteins, DNA, and lipids. 
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The resulting microenvironmental oxidative stress is toxic to various parasites 
and, in order to counteract this, pathogens are equipped with specific ROS-
detoxifying mechanisms as well as DNA repair mechanisms [47]. Most 
intracellular parasites studied possess antioxidant and DNA repair enzymes. In 
vitro assays have implicated the role of ROS in the toxoplasmacidal activity of 
human monocytes and interferon gamma-activated human macrophages. ROS 
induces DNA damage, which includes a multitude of oxidized base lesions, 
abasic (AP) sites, single- and double-strand breaks containing 3′ sugar fragments 
or phosphates and all of these are invariably cytotoxic and/or mutagenic if not 
repaired. Nearly all oxidatively induced DNA lesions (except double-strand 
breaks), as well as single strand breaks, are repaired via the DNA base excision 
repair (BER) pathway in organisms ranging from E. coli to mammals [51]. 
D. Toxoplasma AP endonucleases 
Repair of abasic sites is achieved through BER, and AP endonucleases 
are the rate-limiting enzymes in this pathway. Limited work has been performed 
to date to characterize AP endonucleases in protozoa. AP endonucleases have 
been studied in kinetoplastid parasites Trypanosoma cruzi and Leishmania major 
[71]. Over-expression of the L. major AP endonuclease (LMAP), which is an 
APE1 (ExoIII) homologue, protects the protist from DNA damage. The crystal 
structure for LMAP has recently been solved, and it largely resembles other 
APE1 orthologues including TgAPE. It has been reported that Plasmodium 
falciparum predominantly uses long-patch BER as opposed to short-patch BER, 
which is the predominant pathway in most other species including human [51]. 
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Our study confirms the presence of two AP endonucleases in apicomplexan 
Toxoplasma gondii, the Mg2+-dependent TgAPE and Mg2+-independent TgAPN.  
TgAPE is a homologue of the human APE1 and TgAPN is a homologue of 
S. cerevisiae APN1.TgAPN is absent in mammals, which makes it a promising 
drug target. Although TgAPE has a human homologue, it is considerably 
divergent and can also be considered a possible drug target. TgAPE does not 
have a redox domain as its human counterpart. Interestingly, TgAPE is more 
closely related to plant APEs than metazoans. ExoIII and EndoIV enzymes have 
no structural similarities to each other [59,60], which makes it unlikely that 
TgAPE and TgAPN have structural similarities. The only similarity between 
TgAPE and TgAPN is they both remove abasic sites. The presence of two 
structurally different enzymes with the same function is an example of 
convergent evolution. The evolution of two distinct proteins to catalyze the same 
enzymatic reaction supports the importance DNA repair in Toxoplasma. 
E. Size and localization of TgAPE 
 While TgAPE does not appear to be abundant or important in protecting 
Toxoplasma from MMS-mediated DNA damage in tachyzoites. I speculate that 
TgAPE may be critical during another life cycle stage. Another interesting finding 
from our studies is that TgAPE exists as two forms, the shorter one being in the 
cytoplasm and possibly the apicoplast. The presence of truncated APE1 in the 
cytoplasm is not without precedent; the distribution of human APE1 (hAPE1) in 
the nucleus, mitochondria, and cytosol is in a dynamic equilibrium [83]. Several 
recent studies indicated the presence of nuclear hAPE1 in the mitochondria 
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(mtAPE), suggesting that hAPE1 is not altered after its mitochondrial import [83]. 
The full length hAPE1 has an N-terminal nuclear localization sequence. Deletion 
of the first 33 amino acids of hAPE1 results in translocation to the mitochondria, 
and increases the specific activity of mtAPE (truncated hAPE1) by 3-fold [83]. 
Interestingly, cytoplasmic localization of hAPE1 has been observed in several 
tumors and correlates with a poor prognosis [97]. Localization of TgAPE to the 
apicoplast could be a significant finding as this plastid-like organelle houses its 
own 35 kb genome that is essential for Toxoplasma viability. Genes encoding 
proteins involved in DNA replication or repair are absent from the apicoplast 
genome [66]. Certain genes encoding plastid DNA replication enzymes are, 
however, present in the nuclear genome, with the protein being imported into the 
plastid post-translationally. This lends evidence to the possibility of TgAPE being 
translocated into the apicoplast to serve as a repair enzyme for apicoplast DNA. 
In addition to its endonuclease activities, hAPE1 can regulate transcription by 
virtue of its redox activity; the TgAPE homologue, however, has a valine residue 
in the position equivalent to cysteine residue 65, which is essential for redox 
activity in the human enzyme [84]. 
F. Size and localization of TgAPN 
 The identification of TgAPN as a major AP endonuclease important for 
DNA repair in Toxoplasma is the first demonstration that such enzymes may be 
attractive drug targets against intracellular protozoan pathogens. TgAPN is more 
abundant than TgAPE at both protein and mRNA levels. In other species, it has 
been shown that there is usually a dominant AP endonuclease that handles the 
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bulk of DNA repair [71]. Native TgAPN appears larger than the rTgAPN, which 
may suggest post-translational modifications (PTMs). Although no PTMs have 
been identified for APN1 homologues to date, several have been identified for 
hAPE1. Human APE1 has previously been shown to be ubiquitinated, 
phosphorylated, nitrosylated, and acetylated [98]. Such PTMs are involved in the 
function of the protein as well as its localization. TgAPN, like its yeast 
homologue, localizes to the nucleus (Figure 19). The APN1 C-terminus is rich in 
basic amino acids and includes two lysine/arginine clusters related to the nuclear 
transport signals of some other proteins. Deletion of the C-terminal sequences 
associated with nuclear localization resulted in the accumulation of cytoplasmic 
APN1 [99]. These delocalized derivatives also failed to restore wild-type 
resistance to oxidative or alkylating agents in mutant strains [85]. APN1 deficient 
cells (apn1Δ) show increased mutation frequencies in mitochondrial DNA 
(mtDNA), suggesting that APN1 is also important for mtDNA stability [85]. In our 
studies, no appreciable levels of TgAPN were detected outside the nucleus of the 
parasite. 
G. Enzymatic analysis of TgAPE and TgAPN 
 Our findings show that both recombinant TgAPE and TgAPN are 
enzymatically active. Like its human homologue, TgAPE is Mg2+ dependent and 
requires the presence of magnesium ions for DNA repair activity. The divalent 
metal ion dictates the directionality of bond cleavage by stabilizing the O3′ 
leaving group, either by direct ligation or via a water molecule in the first 
hydration shell of a magnesium ion [51]. APN1 homologues require zinc ions to 
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have enzymatic activity [51]. Although TgAPN displays DNA repair activity 
without zinc ions, it is thought that the Zn2+ ions are incorporated into the enzyme 
during folding in the bacteria. APE requires two magnesium ions while APN 
requires three zinc ions [51]. Using the recombinant proteins, we were able to 
establish that both enzymes had similar Michaelis-Menton Km values of 26.2 and 
21.1 nM for TgAPN and TgAPE, respectively. The Vmax values were 1458 and 
110,070 RFU/µg/s for TgAPN and TgAPE, respectively, indicating that the 
turnover rate was approximately 75 times faster for TgAPE (Figure 17). These 
data suggest that despite the low abundance of TgAPE in tachyzoites, TgAPE 
may play an important role in DNA damage repair in Toxoplasma. Furthermore, 
AP endonuclease assays performed using Toxoplasma lysate in the presence or 
absence of EDTA (to chelate Mg2+) demonstrated that TgAPN does not account 
for 100% of the total AP endonuclease activity. 
H. TgAPN over-expression protects parasites from MMS 
Cells would be expected to be protected from DNA damaging agents 
when AP endonucleases are over-expressed. Furthermore, expression of 
Trypanosoma cruzi and Leishmania major AP endonucleases in E. coli deficient 
in DNA repair confers protection against DNA damaging agents. Over-expression 
of TgAPN conferred protection against MMS. The increased levels of TgAPN 
protein in the over-expressor facilitated an increased capacity to repair DNA 
damage compared to the wild-type parasites. Over-expression of TgAPE 
surprisingly did not yield any protection to MMS. There are a few possibilities that 
may explain this result. Unlike APN1 homologues, APE1 enzymes do not 
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possess nucleotide incision repair. Nucleotide incision repair activity (NIR), which 
can directly incise 5′ to specific oxidized bases, e.g., α-deoxyadenosine (α-dA/T) 
or dihydrouridine (dHU/G), to create a 3′-hydroxyl group for DNA repair synthesis 
[94]. Another explanation for TgAPE over-expression failing to confer protection 
to MMS is that necessary co-factors or other proteins needed to facilitate TgAPE 
function are not expressed to sufficient levels. Finally, we only tested the 
recovery to MMS-mediated damage. It is possible that TgAPE is reserved for 
responding to DNA damage mediated by other agents. 
I. TgAPN conditional knockout 
 In humans, the knockout of the main AP endonuclease is not viable and 
only cells with low levels of APE can escape death [51]. In mammals, complete 
deletion of APE1 is embryonically lethal [51]. Attempts to make a knockout of 
TgAPN in tachyzoites have been unsuccessful. A conditional knockout approach 
to disrupt TgAPN was successful, demonstrating that the TgAPN genomic locus 
can be disrupted and highlighting the probability that TgAPN is essential for 
parasite survival. APN1 and APN2 have been knocked out in S. cerevisiae 
producing viable yeast cells. APN1 has also been knocked down in 
Caenorhabditis elegans. In both cases, the depletion of APN did not prove lethal 
but the cells were particularly susceptible to DNA-damaging agents. The 
conditional knockout strategy that we used to diminish TgAPN levels was a tet-off 
system [51]. The conditional knockout was created in a special RH-based 
parasite line (TATi), which has been transfected with tet-transactivator, tTA, 
composed of a TetR-VP16 fusion. The regulatable copy of TgAPN was made in a 
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vector containing TetOSAG1 promoter elements. Although the presence of TetO 
promoter elements attenuates the SAG1 (Toxoplasma surface antigen 1) 
promoter, it still proved to be stronger than the endogenous TgAPN promoter. 
Consequently, expression of ectopic TgAPN was higher than wild-type levels. 
Down regulation of ectopic TgAPN could be achieved through the inclusion of 
ATc in the culture, but TgAPN levels did not fall significantly below wild-type 
levels. Inability to completely down-regulate protein levels using the Tet-off 
system has been previously documented in Toxoplasma [78]. The inability to 
deplete TgAPN levels in the conditional knockout limited the use of the clone to 
study susceptibility of the parasites to DNA-damaging agents, but our data did 
show a mild impaired DNA damage response upon depletion of TgAPN.  
J. TgAPN knockdown using a destabilization domain 
 An alternative to the conditional knockout is the destabilization domain, 
which does not rely on a strong exogenous promoter. The native TgAPN is 
tagged at the C-terminus with a destabilizing domain (DD), which ensures that 
wild-type levels of TgAPN are maintained in the parasite; the TgAPN-DD fusion 
can then be depleted to an amount lower than wild-type using a ligand that binds 
the DD [78]. The DD utilizes an engineered version of human FKBP12 (FK506 
binding protein) fused to the N or C terminus of a target protein, promoting 
degradation of the fusion protein [92]. FKBP, or FK506 binding protein, is a family 
of proteins that have prolylisomerase activity, thus their destabilizing effect on 
proteins. Prolylisomerase enzymes interconvert the cis and trans isomers of 
peptide bonds with the amino acid proline [100]. Proline is unique among amino 
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acids in having a relatively small difference in free energy between the cis 
configuration of its peptide bond and the more common trans form. Proline has 
an unusually conformationally restrained peptide bond, this because proline has 
a cyclic structure with its side chain bonded to its secondary amine nitrogen. 
FKBP12 is notable in humans for binding the immunosuppressant molecule 
tacrolimus (originally designated FK506), which is used in treating patients after 
organ transplant and patients suffering from autoimmune disorders [92]. In the 
presence of a ddFKBP ligand, degradation is mitigated, allowing regulation of 
protein levels in cells. Shield-1, a cell-permeable ligand, binds tightly to the 
destabilizing domain and prevents degradation, providing small molecule control 
over intracellular protein levels [100]. Our findings show that the levels of TgAPN 
were significantly decreased when tagged with a destabilization domain in the 
absence of Shield-1. Trace amounts of TgAPN were detected by Western blot. 
Immunofluorescence showed that some TgAPN protein was found in what 
appears to be cytoplasmic vesicles. The vesicular localization of TgAPN could 
represent the protein in the proteosome being degraded. Despite the low levels 
of TgAPN still left in the parasite, little or no TgAPN was detected in the nucleus, 
its target organelle. The TgAPN-DD parasites are viable under normal culture 
conditions, consistent with the yeast APN1 knockout [101]. Viability of the 
knockdown parasites decreases significantly in the presence of MMS, illustrating 
the reliance Toxoplasma places on TgAPN for DNA repair. 
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K. TgAPE does not compensate for loss of TgAPN 
 To rule out the upregulation of TgAPE to compensate for the loss of 
TgAPN, mRNA and protein levels were analyzed. In other species, such as S. 
cerevisiae, loss of one AP endonuclease can be offset by another AP 
endonuclease to preserve DNA integrity. The viability of TgAPN knockdown 
parasites could be explained by the fact that both TgAPE and TgAPN carry out 
the same function of repairing abasic sites. The levels of TgAPE did not increase 
in either the conditional knockout or the TgAPN-DD clone. On the other hand, we 
have demonstrated that although TgAPE has very low abundance in the parasite, 
it has a very high activity in repair of abasic sites compared to TgAPN in vitro. In 
other words, TgAPN is a very active enzyme that can repair DNA damage at very 
low levels. To completely rule out TgAPE compensation following loss of TgAPN, 
a double knockout of both enzymes might be necessary. This approach is 
complicated by our inability to isolate viable parasites following attempts to 
knockout TgAPE or TgAPN. Therefore, a knockdown approach would have to be 
pursued, which suffers the caveat of not fully depleting protein levels. Despite 
these caveats, a double knockdown of TgAPE and TgAPN is expected to 
dramatically impact parasite growth, especially following DNA damage.  
L. Conclusion 
 In conclusion, the genetic approach supports the hypothesis that the base 
excision repair pathway is important for Toxoplasma survival in an intracellular 
environment. AP endonucleases are the rate limiting enzymes in BER and 
targeting the abundant abasic endonuclease (TgAPN) would render the parasites 
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unable to survive in the intracellular environment. Humans do not possess APN1 
homologues, and the TgAPN enzyme is structurally unrelated to human APE1, 
making it an attractive drug target. 
Although TgAPN has been shown to be important for DNA repair, the 
importance of TgAPE in Toxoplasma DNA repair cannot be overlooked. The 
TgAPN knockdown under the control of the destabilizing domain did not 
definitively prove that TgAPN is an essential gene. However, disrupting the 
TgAPN genomic locus in the conditional knockout and inability to knock out the 
TgAPN gene with conventional homologous recombination shows that TgAPN is 
likely to be essential. There is the possibility that TgAPE might be compensating 
for the loss of TgAPN despite no increase in TgAPE protein. In other species, 
such as E. coli, loss of one AP endonuclease is compensated by another AP 
endonuclease. This redundancy might explain why Toxoplasma is viable even 
with very low levels of TgAPN. 
Both TgAPN and TgAPE catalyze the same enzymatic reaction, cleaving 
the phosphate backbone of DNA 5’ of the abasic site. Enzymatic activity assays 
have shown that both recombinant as well as native TgAPE and TgAPN have 
activity. Whether there is a predominant AP endonuclease operating in 
Toxoplasma remains to be resolved. Native TgAPN appears to be more active 
when enzyme activity is tested from Toxoplasma lysate, i.e. TgAPN shows 
greater than 50% of total activity when TgAPE is inhibited by magnesium 
chelation. Determining the activity of TgAPN by inhibiting TgAPE activity in 
Toxoplasma lysate assumes no other enzyme other than TgAPN and TgAPE can 
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process abasic sites in the parasite. There may be other enzymes that in the 
parasite including glycosylases that can process abasic sites. Recombinant 
TgAPE protein turns over substrate 75 times faster than recombinant TgAPN. 
The apparent discrepancy between recombinant and native proteins enzymatic 
activity could be an in vitro artifact, or could be explained by the possibility that 
TgAPN might be post-translationally modified, which in turn might augment its 
activity. 
TgAPE may be an important DNA enzyme involved in apicoplast DNA 
repair. Curiously, over-expression of TgAPE provided no protection from MMS-
induced DNA damage in the parasite. This result could be explained if the 
primary role of TgAPE is to repair apicoplast DNA. Moreover, it would be 
expected that the higher substrate turnover observed in vitro would not 
necessarily translate into an in vivo setting if TgAPE only repaired apicoplast 
DNA. 
TgAPE is considerably diverse compared to the human APE1 and, if 
found to be critical for Toxoplasma proliferation could also be further explored as 
a drug target against Toxoplasma infection. 
M. Future studies 
 The first study will be to test if the TgAPN knockdown parasites are viable 
in an in vivo environment. Mice will be infected with the destabilization domain 
knockdown parasites and a control mouse group infected with an equal number 
of wild-type parasites. The result expected is that the TgAPN knockdown 
parasites would be more susceptible to the mouse immune system. The mice 
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infected with TgAPN knockdown parasites would thus be expected to survive 
longer after infection compared to mice infected with wild-type parasites. 
 The size disparity between the recombinant TgAPN and the larger native 
TgAPN suggests post-translational modification(s) (PTMs). An investigation to 
determine the post-translational modification would be important in 
understanding the regulation and function of the protein. Post-translation 
modifications can be detected using specific antibodies to a variety of PTMs. To 
determine PTMs on TgAPN using specific antibodies, the native TgAPN protein 
will first be immunoprecipitated from wild-type parasite lysate using the TgAPN 
antibody and specific antibodies used to identify the PTMs on Western blots. An 
alternative approach to determine PTMs on TgAPN would be to use mass 
spectroscopy. Mass spectroscopy is a powerful tool used for protein 
identification, structural characterization, and identification of post-translational 
modifications.  
 Finally, investigation into the cleavage and localization of TgAPE would be 
interesting. Human APE1 is cleaved at the N-terminus and localized to the 
mitochondria [86]. TgAPE is also cleaved at the N-terminus and this may affect 
its localization to other organelles such as the apicoplast. Different truncations at 
the N-terminus of TgAPE coupled with tags on both the N-terminal and C-
terminal ends would help determine localization as well as cleavage points. The 
localization can be determined by immunofluorescence and the cleavage 
products monitored by Western blotting. Localization of a DNA repair enzyme in 
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the apicoplast would be an important finding as there is no knowledge on DNA 
repair mechanisms of apicoplast DNA. 
2. Aim 2: Pharmacological inhibition of TgAPN 
A. Summary of Aim 2 results 
 Work in Aim 2 identified a small molecule, 4491-0277, that can inhibit 
TgAPN enzymatic activity as well as the growth of Toxoplasma in vitro. 
Compound 4491-0277 was identified through a high-throughput screen against 
rTgAPN enzymatic activity. 4491-0277 was able to inhibit parasites at 
concentrations that did not produce overt toxicity to the human host cells. 
B. Limitation of current drug treatments against toxoplasmosis 
The frontline treatment for Toxoplasma, pyrimethamine and sulfadiazine, 
is limiting for a number of reasons. Both drugs target the folic acid synthesis 
pathway needed for both DNA and RNA synthesis. Pyrimethamine inhibits 
dihydrofolate reductase (DHFR), while sulfadiazine inhibits dihydropteroate 
synthase (DHPS). The drugs cause severe side effects, particularly after 
prolonged use, which is required in cases of chronic toxoplasmosis. The 
inhibition of folic acid synthesis results in hematological problems such as bone 
marrow suppression, characterized by megaloblastic anemia and leucopenia. 
Sulfadiazine, a sulfonamide, can cause life threatening skin conditions such as 
Steven-Johnson syndrome and toxic epidermal necrolysis. The adverse effects 
are more pronounced in the immunocompromised, the patient population that 
most commonly suffers from recurring episodes of acute toxoplasmosis. 
Additionally, some strains of Toxoplasma have developed resistance to the 
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current drugs. There is also a paucity of treatments that can be safely 
administered during pregnancy to treat toxoplasmosis acquired in utero. Thus, 
there is an urgent need to identify and develop new drug targets against 
Toxoplasma infection. Additionally, it is hoped that such novel therapies would 
also have utility against other apicomplexan parasites, particularly if the therapies 
are targeted against crucial molecular targets that are similar in protozoa. 
Our genetic studies have shown that the base excision repair pathway is 
important in the viability of parasites in their intracellular environment. Disrupting 
BER by depleting TgAPN resulted in increased susceptibility of Toxoplasma to 
DNA damage. Thus, TgAPN may be a promising drug target against Toxoplasma 
infection. Targeting TgAPN in Toxoplasma is likely to be specific because 
humans and other mammals do not have an APN1 homologue. Inhibiting TgAPN 
with small molecule inhibitors would therefore not be expected to have such 
severe side effects as those seen in targeting the folate synthesis pathway.  
C. TgAPN as a probable drug target 
DNA repair machinery has been targeted in the treatment of various types 
of cancers [69]. Some treatments induce direct DNA damage to overwhelm 
repair mechanisms resulting in death of tumor cells [69]. Inhibition of the BER 
has also been explored widely as a drug target against cancer [69]. Several 
compounds have been developed to inhibit glycosylases to sensitize cancer cells 
to alkylating agents [102]. The most convincing studies on targeting BER in 
cancer have been done by inhibiting human APE1 in brain tumors to sensitize 
the cancer cells to radiation [70]. Inhibiting AP endonuclease has thus been 
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proven in a clinical setting to be a good drug target. No work has been done in 
parasites to disrupt their DNA repair pathways pharmacologically. Cancer cells 
are very similar to pathogenic microbes in some respects. Like cancer cells, 
Toxoplasma is proliferative, which in theory would cause increased aberrations in 
its DNA. Toxoplasma and cancer cells are also under constant pressure by the 
immune cells likely to cause DNA damage. Treatment of Toxoplasma infection is 
similar to cancer in that the treatment should be able to prevent or minimize the 
toxicity to normal human cells by only targeting the rogue cells (Toxoplasma and 
cancer cells). 
D. Identification of small molecules that inhibit TgAPN 
To study the viability of TgAPN to function as a drug target against 
Toxoplasma, a high-throughput screen was performed. The high-throughput 
screen was conducted in collaboration with Drs. Mark Kelley and Millie 
Georgiadis against rTgAPN enzymatic activity. The ChemDiv library of drugable 
compounds was used in identifying TgAPN inhibitors. The fluorescent-based 
screening assay described in detail in the materials and methods identified 9 
compounds that had inhibitory activity against rTgAPN. The compounds 
identified were tested against wild-type RH parasites in vitro. Two of the nine 
compounds tested showed significant activity against Toxoplasma tachyzoites 
but no observable toxicity to the host cells. Further characterization showed that 
compound 4491-0277 was more potent than compound C699-0451 in its ability 
to inhibit parasite growth. Compound 4491-0277 had an IC50 of 0.4 µM. The 
human APE1 inhibitor was also tested against Toxoplasma tachyzoites in vitro. 
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The compound proved effective in killing the host cells (human foreskin 
fibroblasts) and only had an effect on the parasites at high concentrations. This 
result highlights differences between the human and parasite AP endonucleases 
and the possibility of targeting them specifically with minimal off target effects. 
Unlike the TgAPN knockdown parasites, compound 4491-0277 inhibits parasite 
growth without having to induce DNA damage. The most likely explanation for 
this is that 4491-0277 inhibits both TgAPE and TgAPN or might have off-target 
effects. 
E. Conclusion 
The pharmacological approach supports the finding that TgAPN is an 
integral enzyme in Toxoplasma’s ability to repair DNA damage. Additionally, the 
use of compound 4491-0277 to inhibit TgAPN has highlighted the possibility of 
targeting Toxoplasma DNA repair machinery to treat infection, possibly providing 
a new approach that overcomes the limitations of the current drug treatments 
targeting the folate synthesis pathway. 
F. Future studies 
More complete toxicological assays are required to determine if compound 
4491-0277 is non-toxic to human cells. Preliminary studies could employ the 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay to 
determine cytotoxicity of the compound, and comet assays could be performed to 
determine genotoxicity. The effect of the compound on replicating human cells 
would also have to be evaluated to determine if there is any inhibition of cellular 
growth. If 4491-0277 proves to have negligible toxicity on mammalian cells, 
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mouse studies can be performed. Mice can be infected with wild-type parasites 
and treated with compound 4491-0277 to determine if the compound can reduce 
parasite infection in vivo. 
Structural studies to determine the mechanism by which compound 4491-
0277 inhibits TgAPN should also be performed. Such studies will help identify or 
design other compounds that may be more potent at inhibiting TgAPN. Crystal 
structures of TgAPN interacting with 4491-0277 may help establish how the two 
bind. Furthermore, compounds 4491-1565 and C699-0451 have structural 
similarities with compound 4491-0277 and can be modified by altering their 
moieties to increase their inhibitory activity against Toxoplasma. 
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CHAPTER 5: SUMMARY 
This dissertation has characterized TgAPN, one of the two AP 
endonucleases in Toxoplasma gondii. The study identifies two AP 
endonucleases in Toxoplasma, a homologue of the human APE1 (TgAPE) and a 
homologue of yeast APN1 (TgAPN). TgAPN is the more abundant AP 
endonuclease and is absent in humans, making it an attractive candidate as a 
drug target. TgAPN over-expression protects parasites against MMS, while 
TgAPE confers no protection. The data also suggests that TgAPN is an essential 
gene due to the inability to generate a genetic knockout. Supporting this idea, it is 
possible to disrupt the genomic locus to create a conditional knockout in the 
presence of ectopic TgAPN. Knocking down the TgAPN protein levels using a 
destabilization domain results in viable parasites that are hypersensitive to the 
DNA-damaging agent MMS. We have also identified the first APN1 inhibitor, 
4491-0277. Compound 4491-0277 inhibits Toxoplasma growth and does not 
have any overt toxicity to the host cells in vitro. In conclusion, TgAPN has been 
identified as an important enzyme for Toxoplasma DNA repair and can be 
pharmacologically inhibited to serve as a drug target against Toxoplasma 
infection. 
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